Bookmark and Share



News

What Is Missing In Pharma's Fatiguing Business Model?
A recent study finds that over half of all drug approvals in the last 10 years have received approval without demonstrating any tangible benefit to the patient! Seriously? Pharmaceutical companies are going to need to radically alter their business models and place the patient at the very epicentre…. Read more here. (Source: Lynne Taylor, PharmaTimes, 4/8/14).
Will China See An End To Pharmaceutical Rebates?
Following recent bribery scandals and increased government oversight in China, many pharmaceutical companies are reconsidering their use of rebate marketing in China. Read more here. (Source: FirstWord Pharma, 4/11/14).
 
Test Your Research IQ with this Fun Quiz, Using Everyday Examples….Can You Beat My Score (9/10)?
These test questions are from one of Dr Steven Pinker's Harvard courses, "Psychological Science." To learn more about his approach and take a shot at his quiz, click here. (Source: The New York Times).
 
Strategies For Working With Real World Data - A FirstWord Report
The pharmaceutical industry must keep abreast of how fast the supply and demand of RWD is occurring and be ready to apply key strategies to manage it. Take the first step and order your copy of Strategies for Working With Real World Data now! (Source: FirstWord, Oct/2013).
 
US Healthcare And Pharmacy Spending Increased In 2013
2013 saw many changes in the healthcare field: Patent Expirations, Price increases, Greater healthcare utilization, Greater use of generic drugs, and New treatments for orphan diseases, as well as new treatments for other diseases like cancer, hepatitis C, multiple sclerosis, and diabetes. So what impact did all of these changes have on overall spending? Read more here. (Source: First Report Managed Care, 4/16/14).
 
What Has France Done To Upset Big Pharma?
In the never-ending battle to decrease ever rising healthcare cost, the french government has introduced the measure allowing pharmacists to substitute prescribed brand-name drugs with cheaper, similar versions. Being the first European country to take such a step, if it is a success, other countries may soon follow. Large drug makers, furious they were not consulted before the law was passed, are now discussing details with government officials. Read more here. (Source: Reuters, 4/10/14).
 
US Government To Save $100 Billion!!
The Congressional Budget Office is saying the Affordable Care Act will cost $100 Billion LESS than expected, and is attributing this to lower insurance premiums. More information available here. (Source: Ryan McDermott, Fierce Government, 4/15/14).
Google Glass - Support For Parkinson
UK researchers are to evaluate the potential of Google Glass to support people with Parkinson's disease by helping them retain their independence for longer.  How are they doing this? Read more here. (Source: PMLiVE, 4/14/14).
Are Oncologists Ready To Embrace Real-World Data?
FirstWord Pharma polled 192 US and EU5 oncologists to gain some insight into the physician perceptive towards real-world data. Read more here. (Source: FirstWord Pharma, 4/14/14).
What Impact Will The Sunshine Act Have On Medical Affairs
Final regulations have recently been released for the Physician Payment Sunshine Law, part of the Affordable Care Act. Will the practice of medical affairs need to change in this new era? Read more here. (Source: Zipher Medical Affiars, LLC).
What treatments are looming in the specialty pipeline?
Advances in the treatment of hepatitis C and various types of cancer could have a dramatic impact on the specialty market as soon as this year, according to Aimee Tharaldson, PharmD, an Express Scripts senior clinical consultant who analyzes the specialty pharmaceutical pipeline. Hep C treatments from Gilead, Abbvie, Enanta, Merck, and BMS could dramatically reduce the prevalence of hepatitis C, albeit at a very high price. There are also important new cancer drugs that could soon enter the market, with 30% of specialty drugs currently in the pipeline being developed to treat various forms of the disease. Read more. (Source: Specialty Pharmacy Times, 4/9/2014)
Webinar: Introduction to the Hepatitis C Impact Monitor (HCIM)
Zitter Health Insights offer this webinar taking place Wednesday, April 30 from 1:00-2:00pm EDT. It will cover 1) What is Hepatitis C Impact Monitor (HCIM)?, 2)Topics we cover and how might that change over time, 3) Awareness and assessment, future category management and administration burden and prescribing. RSVP here. (Source: Zitter Health Insights, 4/16/2014)
Clinical Trials Lack Of Transparency - How easy is it to Misrepresent a Product? One Word - Tamiflu
Is the lack of transparency in clinical trials making it easy for Big Pharma to Misrepresent products? Taking Tamiflu's story of an "industry accepted" practice of selective dissemination of clinical trial results, inconsistencies, and cover ups, this article describes a pivotal moment in the history of medicine, calling for a change in legislation as well as a cultural shift. Are we ready to push for this change? Read more here. (Source: Ben Goldacre, The Guardian, 4/9/14).
Why Are Some Doctors Standing By Gilead's Pricing?
At the recent European Association for the Study of the Liver conference in London, doctors told governments and insurers to look at the big picture; Sovaldi will save payers  from the cost of long-term complications of the disease, besides, oncology drugs are already priced in this range-and excepted…that makes it ok, right? Read more here. (Source: Arlene Weintraub, FiercePharma, 4/11/14).
Can The Nations Healthcare Bill Support Double-Digit Increases In Drug Spending
The recent CVS Caremark report saw a large growth in specialty drugs and is predicting a much greater growth in the next four years, particularly with drugs like Gilead Sciences' Hepatitis C treatment, Sovaldi. Will these new drugs save payers money in the long run, or will the short term be too much to handle? Read more here. (Source: Eric Palmer, FiercePharma, 4/11/14).
 
Are You Involved? You Better Be! ASCO Rating Drugs On Price:Value Ratio!
The American Society of Clinical Oncology is taking a stand against unsustainable pricing on cancer drugs. The group has launched an effort to rate cancer drugs not only on their benefits and side effects, but on their prices as well, and they're recommending oncologist consult its scorecard before deciding on a treatment plan. Read more here. (Source: Tracy Staton, FiercePharma, 3/26/14).
Specialty Pharmacy Considerations for Hemophilia Inhibitors
Hemophilia is a bleeding disorder that is usually passed on through genetics. Donna Haffler, RN, BSN, Walgreens Specialty Pharmacy, and Kirstin Schmidt, RN, national clinical director, bleeding disorders program, Walgreens Specialty Pharmacy, led a session at the NASP 2014 Specialty Pharmacy EXPO on hemophilia inhibitors and their role in specialty pharmacy. Read more. (Source: First Report Managed Care, 4/8/2014)
Managed Care Focus on MS, Hepatitis C, and PAH
During a session at the NASP 2014 Specialty Pharmacy EXPO, Jayne Hornung, RPh, vice president, pharmacy and medical data, Managed Markets Insight & Technology, discussed the effects of multiple sclerosis (MS), hepatitis C, and pulmonary arterial hypertension (PAH) in managed care. Dr. Hornung noted that there are commonalities between these 3 disease states: (1) they have a number of medications in each class; (2) they can require prior authorizations for the medications; (3) they have an injectable formulation; and (4) they have seen recent oral agent approvals. Read more. (Source: First Report Managed Care, 4/7/2014)
2014 Specialty Pharmacy EXPO - Keynote Address
The National Association of Specialty Pharmacy (NASP) recently wrapped up its 2014 Specialty Pharmacy EXPO, which took place in Tampa, FL, from March 31 through April 4. In the opening keynote address, Sandy Robinson, BA, MPA, vice president, Avalere, said, "There will be patients who are underinsured,” noting that we can expect to see a shift from uninsured to underinsured patients, meaning patients are more fiscally responsible for their care now. Read more. (Source: First Report Managed Care, 4/8/2014)
Specialty Drug Approvals in 2013
The year 2013 marked the approval of many new specialty medications, with drug debuts and new indications in areas including oncology, hepatitis C, HIV, multiple sclerosis, and inflammatory disease. This article provides a selection of specialty pharmacy– related FDA approvals and expanded indications for 2013. Read more. (Source: Pharmacy Times, 3/13/2014)
Read the Latest Drug Trend Report: Year in Review
Express Scripts recently published the 2013 Drug Trend Report  which notes that overall drug spend increased by 5.4% in 2013, following several years of declining rate increases. Utilization of traditional prescription medications grew only slightly (0.5%) from 2012 to 2013, but the use of specialty medications increased 2.5%. Overall trend was driven by a 2.4% increase in spend for traditional (nonspecialty) medications and a 14.1% increase in spend for specialty medications, one of the lowest specialty drug trends ever recorded. However, specialty medications contributed an ever-increasing share (27.7%) of total spend that is expected to continue to grow. Read more. (Source: Express Scripts, 2014)
How insurers can cut specialty drug costs
Specialty medication costs continue to rise challenging payers. According to a new Milliman report commissioned by CVS Caremark, health insurers can move prescription benefits from medical to pharmacy coverage to off-set these costs. Such a transition would save up 19.7 percent on specialty drugs, while allowing payers to implement more effective management tools, such as formulary design, utilization management, and preferred or exclusive networks. Read more. (Source: FierceHealthPayer, 4/11/2014)
Is Medicare Making Millionaire Doctors?
For the first time in almost 30 years, Medicare is taking a look at physician payments. Recently released data collected from 880,000 providers paid by Medicare shows payments to almost 4,000 doctors of more that $1M a piece, including seven who received more than 10 M. Could this be right? Is the data wrong? Read here and find out more. (Source: Shannon Pettypiece, Bloomberg, 4/9/14).
 
Submit Your Questions For NHS, NICE, HAS And More
Eyeforpharma will be hosting a panel discussion with Payers/HTAs from across Europe at the Real World Data Conference (April 28-29, London), and want YOUR questions answered to give you true insights into how the EU Payers and HTAs make their decisions. Send questions to Ben Swanson, or view the panel session and the full agenda here. (Source: Ben Swanson, eyeforpharma).
How Is The CMS Planning On Paying For Tailored Evidence-Based Care?
With cancer treatments becoming increasingly individualized and expensive, the Centers for Medicare & Medicaid Services' new Innovation Center is taking specific steps to ensure that all patients receive the best individualized care; cost is not considered in their coverage decisions. So, how do they plan on paying for this care? Read more here. (Source: Peggy Eastman, Oncology Times, 4/25/14).
 
FDA's Temple Pushes Feasibility, Cost-Savings Of Large, Simple Trials
New tools and funding priorities support large, simple trials, now industry needs to get on board to create a more efficient, cost-effective health system… read more and Purchase this Article here. (Source: Sarah Karlin, The Pink Sheet Daily, 4/10/14).
 
Freelancers In HEOR, Market Access & Managed Markets: How To Increase Your Income
Run your own small business? Wish you did? Then you need this program: The Business of Freelancing: Getting to Six Figures. You'll learn everything there is to know about setting up and running your own consulting company from veteran healthcare consultant Debra Gordon, MS. The six-week webinar starts May 7 and includes six, 90-minute programs that you can view live and on demand; access to a private LinkedIn group to continue the discussion; and a 30% discount on one-to-one coaching with Debra.
 
And it's only $249! Plus, there's a money-back guarantee within 30 days if you're not completely satisfied.
 
Click here to learn more and register.
Stay Up To Date With FirstWord Pharma PLUS - Subscribe Today!
This personalized resource provides coverage from over 1,200 international news sources, 2,000 medical journals, 100 medical conferences, 120 regulatory bodies, 13,000 products, 3,500 companies, and 120 medical conditions as well as Physician Views poll data and 7 years' worth of searchable news archives. Subscribe Today. (Source: FirstWord Pharma).
 
Are You Up To Date With New Specialty Drugs?
The year 2013 marked the approval of many new specialty medications, with drug debuts and new indications in areas including oncology, hepatitis C, HIV, multiple sclerosis, and inflammatory disease. This article, New Specialty Drugs, provides a selection of specialty pharmacy-related FDA approvals and expanded indications for 2013. (Source: Stacey Ness, Pharmacy Times, 3/13/14).
 
Despite Decreases, Diabetes Cost Still Remain High
A recent study has found that Diabetes out-of-pocket cost have lowered but overall expenses remain high. For more findings on this study, read here. (Source: FirstWord Pharma, 4/9/14).
 
Sebelius Resigns… What Does This Mean For ObamaCare?
Kathleen Sebelius, Secretary of Health and Human Services has turned in her resignation to President Obama, after the troubling roll out of the Affordable Care Act.  Read here to find out more about who the president has nominated to take her place. (Source: Michael D. Shear, The New York Times, 4/10/14).
 
The WHO Calls For Realistic Pricing Of Hepatitis C Medications
The World Health Organization has released guidelines, strongly recommending recently approved drugs to treat hepatitis C, but like so many others, they are calling on the drug makers to set a realistic price making the drug affordable and obtainable for the patients that need it. Read more here. (Source: First Report Managed Care, 4/9/14).
 
Now Available! The National Directory Of Healthcare Payers & Providers For Your State
Save Big Money! You don't need to buy directories for the whole country - get all of the health plan payers and providers for just the state of your choice in Excel format on CD-ROM. Available for purchase here. (Source: Managed Care Information Center).
 
Is Big Data Really All It's Cracked Up To Be?
Everyone seems to be talking about Big Data, wHether you're analyzing it, collecting it, praising it or hiding from it; but just how far does big data reach? What can Big Data do, and maybe more importantly, what can't it do? Read more here. (Source: Gary Marcus, The New York Times, 4/6/14).
Should Biosimilar Medicines Be Subject To HTA Processes
Biosimilars present a range of challenges to both regulators and HTA entities. The number that are available on markets worldwide still is low, which means that experience with their assessment is limited. OHE convened a one-day roundtable specifically to discuss whether and how biosimilars should be evaluated from a health economics perspective. Download a summary of that discussion here with this OHE Briefing. (Source: Office of Health Economics, 4/9/14).
 
Can You Draw 7 Perpendicular Red Lines Using Green & Transparent Ink? Ask The Expert!
The pain of being the only engineer in a business meeting is perfectly illustrated in the comedy sketch, "The Expert." Do Yourself a favor an watch this video now please! (Source: EDW Lynch, 3/31/14).
 
Why Are Patients Not Filling Prescriptions?
A recent study conducted in Quebec has found that nearly 1/3 of patients never fill their prescriptions. Is it drug cost, patient gender, or age? Read here to find out. (Source: Nicholas Bakalar, The New York Times, 4/7/14).
 
Who's Interested In Making Treatment More Affordable?
In this video, Dr Jeffrey Dunn, Senior Vice President, VRx Pharmacy Services, LLC, discusses benefit design and the lack of incentives to chose less expensive medications. Dr David Quinn, Gemtourinary Medical Oncologist, USC, Keck School of Medicine, talks on biosimilars and how active management tools can help providers and patients understand the value of therapy options that provide equal benefits to costlier drugs, but for less out-of-pocket costs. Watch video here. (Source: AJMCtv).
 
Gilead's New Hepatitis Drug - The Cost Could Be Far Greater Than Its $84,000 Price Tag!
Express Scripts is warning that the price of Gilead Sciences' Sovaldi is unsustainable and will break the country. If everyone with hepatitis C was treated with Sovaldi, the cost would exceed $300 billion - companies simply will NOT be able to handle that! So, what is action is Express Scripts calling for? Read here to find out. (Source: Matthew Dennis, FirstWord Pharma, 4/8/14).
Effective Pharma KAM Teams - The Essential Factors Driving Performance
Key Account Management (KAM) is now the tool of choice, for many pharmaceutical companies wanting to influence product adoption, improve sales volume and increase product revenue, but too many companies are still engaging with it half heartedly. What are the key ingredients of KAM team? What talents should you look for? How can you effectively change corporate culture to fully exploit all that KAM has to offer? Purchase this FirstWord report here. (Source: FirstWord, January 2014).
ISPOR Wants You! Call For Abstract/Proposal Reviewers
Vonlunteers are needed to review research abstract, workshop proposal, and issue panel proposal submissions as a member of the Congress Review Committees. If you are interested in participating on this review committee for the ISPOR 17th Annual European Congress, apply here. (Source: ISPOR).
Tools For Health Care Decision Making - From ISPOR, AMCP & NPC
The Comparative Effectiveness Research Collaborative Initiative is a collective effort among the Academy of Managed Care Pharmacy (AMCP), the National Pharmaceutical Council (NPC), and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) to provide tools for decision makers to assess studies that use non experimental methods important to comparative effectiveness research. Read more here. (Source: Elsevier, Value in Health, March/April 2014).
Questionnaire - Assessing Relevance And Credibility Of Modeling Studies
This report by Caro et al. describes a consensus-based 15-item questionnaire to help decision makers assess the relevance and credibility of modeling studies to help inform health care decision making. More information here. (Source: Elsevier, Value in Health 17, March/April 2014).
Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire
This report by Jansen ae al, describes a consensus-based 26-item questionnaire to help decision makers assess the relevance and credibility of indirect treatment comparisons and network meta-analysis studies to help inform health care decision making. Read more here. (Source: Elsevier, Value in Health 17, March/April 2014).
Should Observational Studies Be Used In Health Care Decision Making?
This report by Berger et al. describes a consensus-based 33-item questionnaire to help decision makers assess the relevance and credibility of observational studies to help inform health care decision making. More information available here. (Source: Elsevier, Value In Health 17, March/April 2014).
Market Access Didn't See This Coming….
The AIDS Healthcare Foundation (AHF) has written letters to US state Medicaid directors suggesting they block Gilead Sciences' Sovaldi from inclusion in their drug formularies, in hopes of securing a more reasonable price. The $1000 per pill price tag for this drug represents a 279,000% retail markup- leading patients, payers and providers asking; when is enough, enough? Read AHF's letter to state Medicaid directors here. (Source: AHF, 1/29/14).
 
AMCP Specialty Pharmacy Conference Sells Out
Were you there? Feedback from this year's event was very postive. If you missed it or want to relive the experience you can read the blog from AMCP's Annual Meeting & Expo here. (Source: AMCP, April 2014)
What Do You Need To Know About Value Based Assessments And Their Impact?
PruceConsulting has produced a detailed report on the NICE proposals for value based assessment, explaining what you need to know about value based assessments and their potential impact. More information available here. (Source: David Pruce, Pruce Consulting).
 
Payer Engagement - How Does Big Pharma Do It?
During the Real World Data conference, April 28-29th in London, big pharma leaders such as Pfizer's James Harnett, Eli Lilly's Jessamy Baird, and Janssen Diagnostics' Nigel Hughes, will be sharing how they have created very effective payer engagement strategies. More information available here. (Source: Ben Swanson, linkedin).
Download Keynote from AMCP's Specialty Rx Conference
Rebecca M. Shanahan, CEO of Avella, delivered the keynote at AMCP's Specialty Pharmacy Conference 2014. The presentation focused on the optimal role that specialty pharmacies play in connecting the healthcare industry and improving patient outcomes. It is available for download here. (Source: AMCP, 4/4/2014)
Payer Engagement - How Does Big Pharma Do It?
During the Real World Data conference, April 28-29th in London, big pharma leaders such as Pfizer's James Harnett, Eli Lilly's Jessamy Baird, and Janssen Diagnostics' Nigel Hughes, will be sharing how they have created very effective payer engagement strategies. More information available here. (Source: Ben Swanson, linkedin).
NICE: Power To The People - Your Voice Has Been Heard!
NICE has recently taken consultation with patients and doctors into consideration regarding Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), leading the organization to reverse its prior decision to restrict access. Read more here. (Source: Thomas Meek, PMLiVE, 4/4/14).
 
So What Exactly Is Your Real-World Data Strategy?
Fail to prepare…and prepare to fail. This risk hangs over drug companies without a planned approach to using real-world data to support their products. Read more here. (Source: Evidera: the Evidence Forum, March 2014).
Will Cost-Effectiveness Evidence Play A Role In Future US Healthcare Decisions?
In an OHE Lunchtime Seminar, Dr James Chambers reviews the current use of cost-effectiveness analysis in the US and explores the potential value of including it in decisions about coverage for medical technology, particularly under Medicare. More information available here. (Source: OHE, 4/1/14).
Negotiating Patient Access - A Matter Of Culture And Stamina
The life science industry will need to continue to focus on patient access as a core element of their business and product strategy, and for commercial success, marketing plans will need to address the thinking and decisions of payers. Read more here. (Source: Evidera: the Evidence Forum, March 2014).
 
ISOQOL Announces New Special Interest Group
Join ISOQOL's new Health Preference Research Special Interest Group when you join ISOQOL. First meeting will be held during ISOQOL Annual Conference, Oct 15-18 in Berlin. More information here. (Source: ISOQOL, Linkedin).
 
Methods For Selecting And Measuring Endpoints That Are Meaningful To Patient In Rare Disease Clinical Development Programs
Stakeholder groups, including regulators, payers, policy makers, and patients, have demanded patient-centeredness in rare disease drug development programs. More here. (Source: Evidera: the Evidence Forum, March 2014).
Rare Disease Treatments - Evidence, Value, Insights
Rare, or "orphan", diseases are those diseases which affect a small percentage of the population. In the last 30 years, there has been a larger focus on addressing the treatment needs of these diseases. More information here. (Source: Evidera: the Evidence Forum, March 2014).
 
Infographic - Facts And Figures On Bleeding Disorders
In the April 2014 issue of the Journal of Managed Care & Specialty Pharmacy, Accredo, Express Scripts, provides the following infographic: Bledding Disorders: Complex And Costly; Specialized Care Solutions Required. See more here. (Source: JMCP, vol 20 num 4, April 2014).
 
Have You Heard Of The GRACE Checklist Yet?
Researchers have developed and tested a checklist that aims to evaluate comparative effectiveness research and distinguish real-world studies that are good enough for decision-making about treatments, called the Good ReseArch for Comparative Effectiveness (GRACE) checklist. Find out more here. (Source: Medical Marketing & Media, 4/1/14).
 
Sanofi Becomes First Major Pharma Company To Appoint Chief Patient Officer
As the pharma industry moves toward a more patient-centric business model, smaller firms have been making chief patient officer appointments, but with naming Dr Anne Beal as chief patient officer, Sanofi has become the first top 10 company to create such a role.  What exactly does a chief patient officer do? Read more here to find out. (Source: PMLiVE, 4/1/14).
Precision Health Economics' Has A New Chief Operating Officer
Bristol-Myers Squibb Executive, Ross Maclean, has recently been named Chief Operating Officer (COO) at Precision Health Economics. To find out more about Dr Maclean or Precision Health Economics' vision of growth, read more here. (Source: PR Newswire, 3/31/14).
 
Are Itemized Price Lists The Next Trend In Healthcare?
As US customers are facing a larger share of the insurance cost burden with employers, today's hospitals find themselves under increasing pressure to provide an accurate view of the cost of patient care. Read more here. (Source: David Beto, nomise).
Croatia - ISPOR Pharmacoeconomic Guidelines Around The World - Available Now!
The ISPOR Pharmacoeconomic Guidelines Around The World provides a comparative table of 33 key features of a country's pharmacoeconomic (PE) guidelines. Pharmacoeconomic evaluation is an analytical tool to assist decision making in financing and management of pharmaceutical products in a country's health care system or national health insurance program. Read more here. (Source: ISPOR).
Gilead Offers Egypt Discount On New Hepatitis C Drug - A 99% DISCOUNT!
Egypt has the world's highest prevalence of hepatitis C. Gilead has recently finalized an agreement with Egypt, offering the therapy at a price of $900 for a 12 week treatment. That's a 99% discount! This comes as the company faced criticism concerning the $84,000 price tag it put on the same drug for patients in the United States. Read more here. (Source: FirstWord Pharma, 3/30/14).
Canada - ISPOR Global Health Care Systems Road Map - Available Now!
The ISPOR Global Health Care Systems Road Map provides an overview of country-specific health care delivery systems focusing on reimbursement and pricing approval processes for pharmaceuticals, medical devices and diagnostics, which include validated decision models that define decision makers and the decision-making processes for coverage, reimbursement, and pricing. (Source: ISPOR, 2/14).
ISPOR Announces The Establishment of the Marilyn Dix Smith Leadership Award
The ISPOR Marilyn Dix Smith Leadership Award was established in 2014 to recognize one individual each year that has provided extraordinary leadership to the Society. For more information on the reward, or how to make a nomination, please visit the ISPOR website (Source: ISPOR).
Strategies For Working With Real World Data
In Strategies for Working with Real World Data, FirstWord makes a strong case for pharma-payer collaborations, as seen in the compelling work done between Merck and the Regenstrief Institute. More information available here (Source: FirstWord).
 
Did You Miss The Event Everyone Was Buzzing About Last Week?
Speaker presentations from the 2nd Annual Global Pharmaceutical And Medical Meetings Summit are now available! You can still get all the important information and presentations by purchasing access to the Compendium website which includes all speaker-provided content. (Source: World Congress).
What Are The Biggest Factors In Global Pricing Variations?
OHE collaborated on two articles recently published in the Health Economics journal: Value-Based Differential Pricing: Efficient Prices For Drugs In A Global Context, and Pharmaceutical Pricing In Emerging Markets: Effects Of Income, Competitiion, And Procurement. Both are available here. (Source: OHE, 2/25/14).
 
Benefiting From The Promise Of Personalized Medicine
Check out these two recent presentations from the Office of Health Economics' (OHE) Adrian Towse: The Rationale And Procedure For Oncology Pricing And Reimbursement Decisions in England and Setting the Scene: A Health Economics Perspective. Slideshows available here. (Source: OHE, 2/18/14).
How Will The UK Implement The New Value-Based Assessment?
Adrian Towse was speaker at the most recent Health Economists' Study Group, plenary session, and discussed how the UK's new value-based assessment approach to valuing medicines may be implemented. The slideshow from his presentation is available here. (Source: OHE, 1/23/14).
Postdoctoral Researchers - Internship Program Offers Opportunities
Camargo recently added four postdoctoral researchers to its team, helping them gain real-world experience through a unique internship program. Besides being an opportunity to gain experience, the internship can also act as a gateway to a career. Read more here. (Source: Camargo, 3/27/14).
NICE Proposes A More Flexible Approach To Drug Funding, But Will It Be Enough?
As NICE looks to change its evaluation criteria for new medications, taking a broader, societal view of their value, many remain skeptical  of the results. Will it mean fewer rejections? What will it mean for patients towards the end of their lives? NICE consultation will remain open thru June 20, before final changes will be made and implemented in autumn. More information available here. (Source: Thomas Meek, PMLiVE, 3/27/14).
NICE Approves Roche's MabThera To Treat Rare Form Of Vasculitis
The National Institute for Health and Care Excellence recently issued its final guidance giving MabThera the go ahead to treat adults with a rare condition known as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Read more here. (Source: PMLiVE, 3/27/14).
 
Follow These Tips To Avoid Unexpected Medical Cost!
We've all either heard of, or experienced the effects of unexpected medical bills. This video wants customers to know-they have more control over their billing/spending than they may think. Watch How to avoid the nightmare of unexpected medical costs now and learn a few tips to keep you better informed and in control of your healthcare expenditures. (Source: Ed Butowsky, From TheStreet)
 
Walmart - Bringing Retail To The US Health Insurance Exchanges
We all know Walmart, the largest retail company in the United States, but did you know Walmart has also become a major figure in the healthcare industry? After introducing its $4 generic drug program in 2006, Walmart now has its eyes on the health insurance exchanges. What do they think they can do for healthcare? Read all about it here. (Source: Tim Casey, First Report Managed Care, 3/18/14).
Have You Subscribed To FirstWord Pharma PLUS?
This personalized resource provides coverage from over 1,200 international news sources, 2,000 medical journals, 100 medical conferences, 120 regulatory bodies, 13,000 products, 3,500 companies, and 120 medical conditions as well as Physician Views poll data and 7 years' worth of searchable news archives. Subscribe here! (Source: FirstWord Pharma, 2014).
 
NICE Opens Consultation On New Value-Based Assessment Scheme
This new proposal has the potential to increase the number of positive appraisals from NICE, but only if companies offer the very best price to the NHS. What does this mean for NICE's existing 'end of life criteria' or its quality adjusted life years (QALYs) measure? Find out more here. (Source: Matthew Dennis, FirstWord Pharma, 3/27/14).
 
Meta-Analysis: Is It Saving Money, Or Costing More Than We Bargained For?
Clinical studies are difficult to complete and expensive. To solve this problem, the concept of meta-analysis was devised. Taking many underpowered studies and putting them together to form one larger study. Are the results of such studies accurate? More information here. (Source: Christopher Johnson, KevinMD.com, 3/26/14). 
How Real Is The Dallas Buyers Club?
The film, Dallas Buyers Club, revels in the moral dilemma posed by randomized controlled trials of new medicines. What goes on in these clinical trials? Who knows the results? The problem is that even when these trials are completed, the findings are routinely withheld from doctors, researchers and patients. Read more here. (Source: The Economist, 3/24/14).
Hepatitis C - How Much Would You Pay For A Cure?
$84,000 for a 12-week treatment course - that's the price for Gilead Sciences' new hepatitis C drug, Sovaldi. While a cure will dramatically reduce cost related to the disease (liver transplant, risk of liver cancer, or cirrhosis) many fear that not all patients will have access to the drug, because of its high cost. Read more here. (Source: Joe Barber, FirstWord Pharma, 3/21/14).
The National Directory Of Healthcare Payers And Providers For Your State
The most accurate, reliable database for your state on one CD-ROM that helps you connect the health "players" in a state - healthcare systems and their affiliates, physician organizations including IPAs and PHOs, the providers, and managed care organizations-the payers. Available for purchase here. (Source: Health Resources Online).
US Lawmakers Blast Gilead Pricing On New Hepatitis C Drug
Sovaldi is on track to become the most lucrative pharmaceutical product launch…. IN HISTORY! And while lawmakers acknowledge that Sovaldi seems to be a breakthrough treatment, patients will not be cured if they can not afford it! Read more here. (Source: Phil Taylor, PMLiVE, 3/25/14).
NICE Backs Janssen But Denies Bayer
The UK's National Institute for Health and Care Excellence (NICE) has published contrasting guidance for the NHS use of two new cancer drugs. More details available here. (Source: Thomas Meek, PMLiVE, 3/24/14).
 
Sanofi's Zaltrap - Out Of Options And Without NICE Approval
In its final guidance, NICE will not recommend Zaltrap as a treatment for metastatic colorectal cancer. Sanofi appealed the decision and offered to reduce the drug's price through a patient access scheme, but NICE stated it still did not represent an effective use of NHS resources. More information here. (Source: Dominic Tyer, PMLiVE, 3/25/14).
Avella CEO Featured at AMCP's Specialty Pharmacy Conference
Rebecca M. Shanahan, the CEO of Avella Specialty Pharmacy, will be the featured speaker for the Opening General Session of AMCP's Specialty Pharmacy Conferece, which begins April 1 in Tampa. Ms. Shanahan will open the Conference with insights on the roles of payers, patients, specialty pharmacies, and manufacturers in attaining desired health care outcomes. She'll illustrate her insights with examples from Hepatitis-C and oncology treatment. Register here. (Source: AMCP)
PCORI - Empowering Patients
Meet PCORI's Bettye Green. Bettye is a Community Outreach Nurse and Associate Director of Advocacy for the Alliance for Clinical Trials in Oncology at Saint Joseph Regional Medical Center.  She serves on PCORI's Advisory Panel on Assessment of Prevention, Diagnosis and Treatment Options, representing patients, caregivers, and patient advocates. Read more here. (Source: PCORI, 3/7/14).
What Do You Think Of The Proposed NICE Alternative For Value Based Pricing?
Two main changes relying on the concept of a quality adjusted life year (QALY) shortfall, instead of establishing a higher cost per QALY threshold are being proposed.  What do you think? Read more here. (Source: James Raftery, BMJ Group Blogs, 2/14/14).
Breakthrough Hepatitis C Drug Pricing - Is $84,000 Too Far?
U.S. Representative, Henry Waxman, is now taking on high prices in the drug industry, in particular, calling to attention Gilead's breakthrough new drug for Hepatitis C, Sovaldi.  Sovaldi can cost $84,000 per course! Really? Read more here. (Source: Matthew Herper, Forbes, 3/24/14).
US Payer Model May Mirror Europe Sooner Than Expected
In this blog posting, Kent Rogers, Principle Consultant with the Blue Fin Group discusses the US Healthcare Market, The many factors determining pricing, Cost containment, and a look at where our healthcare industry is headed. Read more here. (Source: Kent Rogers, Finsights, 3/20/14).
 
Which Value-Based Reimbursement Model Will Ultimately Align Physicians?
Don't Miss This On-Demand Webinar - Physician Alignment: Which Model Is Right For You? with Greg Mertz, Managing Director Of Physician Strategies Group, LLC. Read more here. (Source: HIN, 2014).
How Does PCORI Decide Where To Place Their Funding?
How does PCORI prioritize the thousands of accumulated ideas, and decide where their funding will go? Meet PCORI Advisory Panelist, John A. Galdo, a clinical pharmacy educator at Barney's Pharmacy in Augusta, GA. He serves on PCORI's Advisory Panel on Improving Healthcare Systems, representing clinicians. (PCORI, 3/7/14).
You Don't Have To Be A Connoisseur To Enjoy The Benefits Of Wine!
What does this freelance medical writer and mother do with her down time? She Drinks Wine of course! Along with enjoying wine, she REALLY enjoys the story behind each bottle of wine, the stories shared while drinking wine-and she loves writing about those stories. Check out her book, Wine on Tuesdays: Be a Serious Wine Drinker Without Taking Wine Too Seriously, available on Amazon.com. Written with her husband, the book aims to de-mystify the world of wine so that all may enjoy it! Learn more about our Featured HE Artist, Debra Gordon, here. If you or someone you know would be interested in becoming an HE Artist, please contact us at HealthEconomics.Com.
 
Can ACOs Succeed in Navigating Bumpy Road Ahead?
According to Aetna's CEO, Chareles Kennedy, they can. He told InformationWeek that ACOs must manage operations while both the provider and insurance industries transition toward value-based payments when fee-for-service reimbursements remain dominant. He also noted that the advancement of HIT is one of the most important components. Read more here. (Source: FierceHealthPayer, 3/19/2014)
Are We Asking Enough of Our Clinical Trial Design?
This Context Matters Blog sugguests that the "goal line for drug development is not simply regulatory approval, but rather reimbursement. Incorporating reimbursement intelligence and sensibilities into clinical trial design requires recognizing this goal line and creating a dynamic process to achieve it." Read more. (Source: Context Matters, 3/10/2014)
Are you up to date on Asia? ISPOR: News Across Asia
ISPOR has released News Across Asia Volume 2 No. 4 (Winter Issue), the Asia Consortium newsletter which regularly covers outcomes research and health policy trends in Asia. Highlighted in this issue: PEOR in Korea, Estimateing Economic Loss Resulting from Irrational Use of Medicines in Mongolia, First Indonesia Pharmacoeconomics Guidelines, ISPOR Asia-Pacific Call for Abstracts and more. Available here. (Source: ISPOR, 3/18/2014)
What Did Roche do with 10,000 Chinese Patient Records?
After gaining access to 10,000 patient records in China, Roche applied its Real World Data strategy to the records and this led them to reduce the patients process from 40 steps to just 9. This improvement dramatically effected outcomes of clinical trials – found out how by reading the article from eyeforpharma. (Source: eyeforpharma, March 18, 2014)
Add this to your book list! The Passionate Economist by Diane Swonk
As the chief economist at Bank One and as an advisor to policymakers, Diane Swonk believes that economics is as much social policy as financial policy. In The Passionate Economist: Finding the Power and Humanity Behind the Numbers, Swonk skillfully reveals how economics is not a hard science, but a behavioral science built on the foundation of human activity. Swonk brings a unique and somewhat unlikely perspective on money and finance. Available on Amazon.com.
What's Trending in Healthcare?
HIN has released the HINtelligence Report, "Healthcare Trends in 2014". Find out about the "trifecta of value-based priorities",6/19/2014 in addition to how healthcare companies fared in 2013 and what trends are expected to emerge in 2014. More information available here. (Source: HIN, March 2014)
Video: Canadian Doctor Politely Corrects Mistaken NC Senator
Speaking before a Senate subcommittee, Dr. Danielle Martin, vice president at the Women’s College Hospital in Toronto, masterfully showed how to smack down a disingenuous politician’s misleading and misinformed questions with courtesy, intelligence and, well, facts. More here. (Source: MSNBC, 3/15/2014)
Video: Meet Grant Jones, Advisory Panelist for PCORI
Grant Jones is the founder and Executive Director of the Center for African American Health. He serves on PCORI's Advisory Panel on Addressing Disparities, representing patients, caregivers, and patient advocates. View Video. (Source: PCORI, 3/7/2014)
OHE Models Incentives for Antibiotic Drug Development
The new OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs. It concludes that traditional incentives for R&D/market exclusivity are likely to be insufficient to spur development, and that uncertainty and risk are too great for price alone to provide sufficient incentive. The most effective solution couples an advance market commitment, at national or supranational level, with careful local pricing. Read more here. (OHE, 3/18/2014)
Come on Down! Your are the next contestant on "What Drug Price Is Right"!
Now that would be an interesting game show! Kent Rogers, Prinicpal Consultant at Blue Fin Group, blogs about the US healthcare market in part 2 of his series. He asks the question, "What Price is Right?". The blog considers the value proposition and ways in which product value is determined (cost-offset vs. cost efficacy). Regardless of either, he notes that pharma and med device companies need to provide a value proposition and improved healthcare for the patient. Read his blog here. (Source: Finsights, 3/17/2014)
Avoiding Convention Chaos: Digital Marketing Strategies To Make Your Efforts Count
Wouldn't you like to be better prepared for ISPOR, AMCP and other major meetings this year? This  tHEORetically Speaking Blog post gives you a before, during and after checklist on how to turbocharge your convention experience. Read more here. (Source: HealthEconomics.Com, 3/13/14).
Orphan Drug Pricing - Will Europe Ever See Consistency?
The role of European pricing negotiations as a key determiner on the success of an ultra-orphan business model were recently highlighted when Alexion lifted its annual guidance following French reimbursement of Soliris. Read more here. (Source: FirstWord Pharma).
 
French Reimbursement For Soliris Provides Boost To Alexion
Alexion's agreement with the French will positively impact reimbursement for Soliris, and even provides reimbursement for shipments of Soliris made prior to January 2014. Read More Here. (Source: Matthew Dennis, FirstWord Pharma, 3/10/14).
Will Canada See Universal Coverage For Oral Cancer Drugs?
A coalition of cancer organizations has reported that oral cancer drugs are not always eligible for reimbursement in certain provinces, and is pushing for universal coverage of oral cancer therapies in Canada. More information available here. (Source: FirstWord, 3/10/13).
 
ACA's Cost Sharing Elimination Expected To Increase Breast Cancer Screening Adherence - But At What Cost?
Follow-on diagnostics are performed after screening mammograms that have suspicious findings - the vast majority of which rule out cancer. The findings in this study, highlight the need for payers & employers to evaluate the quality and value of breast cancer screening follow-on diagnostic patterns. Download available here. (Source: Milliman, 2/24/14).
What Can FirstWord Pharma PLUS, Do For You?
This personalized resource provides coverage from over 1,200 international news sources, 2,000 medical journals, 100 medical conferences, 120 regulatory bodies, 13,000 companies, and 120 medical conditions as well as Physician Views poll data and 7 years' worth of searchable news archives. Sign up for a free trial or Subscribe today! (Source: FirstWord Pharma).
 
Are NICE Committee Members Being Payed Off?
The National Institute for Health and Care Excellence (NICE) is denying claims that the pharma industry influenced new guidance to increase the use of drugs to lower cholesterol. However, a recent story in the Sunday Express has discovered 8 out of 12 members of the NICE panel have financial ties to the drug firms. More information available here. (Source: PMLiVE, 3/13/14).
 
Three Goals Of PCORI Advisory Panels
Joe V. Selby, PCORI's Executive Director, describes why PCORI's Advisory Panels are an essential part of helping PCORI do research differently. Watch video here. (Source: PCORI).
Health IT - The Place To Be - Job Postings Have Tripled Since 2009!
This brief describes trends in online job postings for Health IT jobs since the passage of the Health Information Technology for Economic and Clinical Health (HITECH) Act in February 2009. Health IT job opportunities have been growing by leaps and bounds with no site of slowing down! More information available here. (Source: The Office of the National Coordinator for Health Information Technology, May 2012).
PCORI - Laying The Foundation For Effective Dissemination & Implementation Of Research
Dr. Anne C. Beal, PCORI's Deputy Executive Director and Chief Officer for Engagement, describes how the Patient Engagement Advisory Panel is helping PCORI be patient-centered in all areas of their work. Video available here. (Source: PCORI, 3/7/14).
Campaign Launches To Address Diversity In Clinical Trials - Are You In?
The I'm In campaign is designed to improve health by increasing clinical trial participation among traditionally underrepresented populations, including African Americans, Asian Americans and Hispanics. Visit the I'm In Website to find out how you can get involved. (Source: PhRMA, 3/12/14).
Whitepaper - Updating Systematic Reviews
This report is available in PDF (696 kB) only. People using assistive technology may not be able to fully access information in this file. Available for Download here. (Source: Agency for Healthcare Research and Quality, 3/10/14).
Social Media, Patients And Health Care: What's The Story?
Social Media has revolutionized communication and has been targeted as a way to provide information and support to patients and caregivers, but is it effective? Should social media have a more formal role in health care? Read more here. (Source: Seye Abogunrin, ISPOR Connections, Vol 20, Jan/Feb 2014).
 
Medical Devices - What Countries Are Keeping An Official Positive List
Reimbursement of medical devices is an issue where different practices are observed among different countries.  The objective of this study is to find out whether there are positive lists of medical devices accessible at national or regional levels in Europe, North America, Western Pacific and Western Asia. Get study results here. (Source: Oznur Seyhun, ISPOR Connections, Vol20, Jan/Feb 2014).
When Collecting Patient Data Goes Electronic
The growing use of mobile technologies and the internet is opening new opportunities to capture the patient's voice and  changing modern health care, but will developers ever be able to guarantee the integrity and confidentiality of this data collected through these new technologies? More information available here. (Source: ISPOR Connections, Vol 20, Jan/Feb 2014).
 
Watch Out Big Pharma - Here Comes Carl Icahn
When people think of Carl Icahn, people think of his investments with companies such as Apple and Netflix, but lately he's been active in the upcoming merger of Actavis and Forest Laboratories. What could a move like this mean for big pharma? What could a move like this mean for doctors and patients? Read here and find out. (Source: Steve Brozak, Forbes, 3/4/14).
Survey Finds Preference for Specialty Pharmacies
According to the 2014 PBMI Specialty Drug Report, employers believe specialty pharmacies provide better access to pharmacists and lower costs for specialty drugs. The survey collected responses from 337 employers in the US, representing 14.3 million people. See more results here. (Source: Drug Topics, 2/14/2014)
Stay up to date! Read the latest Specialty Pharmacy Continuum
This issue of the Specialty Pharmacy Continuum (SPC) includes articles about the  specialty pharmacist's role as educator for patient adherence, temperature integrity of specialty drugs and more. In addition to news, the web site includes many of the magazine’s regular features, including new FDA drug approvals, educational reviews, and continuing education. Connect with SPC here. (Source: Specialty Pharmacy Continuum, Vol. 3, Number 1, Winter 2014)
Armada Video Generates Excitement for Upcoming Specialty Pharma Summit
The 2014 Specialty Pharmacy Summit & Expo is scheduled for May 5-9, 2014 at the Wynn Hotel in Las Vegas. It is the largest annual gathering for specialty pharmacy and includes thousands of attendees from pharmacy providers, pharma/biotech manufacturers, payers and many other specialty pharmacy stakeholder organizations. The conference provides an opportunity for all attendees from around the nation to learn about specialty pharmacy while connecting and networking with leading industry executives, professionals and senior decision-makers within the specialty pharmacy channel. Watch video here. (Source: Armada, March 2014)
WEBINAR: Specialty Channel Economics: Strategies to manage three key intelligence gaps
Specialty medicine spending increases are driven by multiple influences across multiple stakeholders. Price inflation, disease prevalence, utilization and site of service are all major factors. As Specialty costs continue to soar, it's imperative that Payers optimize management strategies - from cost sharing, to benefit design, to contracting. Register for this On-Demand webinar from IMS Health here. (Source: IMS Health, March 2014)
Survival of the Most Adaptable: Are You Change-Ready?
As Bob Dylan sang, "Oh the times, they are a changing." This is true in the pharmacy realm where specialty pharmacy is expected to comprise 50% of overall commercial drug plan spend by 2020. Today the market is very different than it was. Do you understand what the future looks like for your organization? This blog post from Shalin Shah, consultant at Blue Fin Group, will shares the essential questions that you need to ask. More here. (Source: Blue Fin Group, 3/7/2014)
Webinar - Roadmap for Success: Integrating Specialty Pharmacy into the ACO Model
Part 3 of this Armada webinar series will discuss the strategic, operational and contractual considerations around integrating specialty pharmacies into ACO models. A variety of panelists will be present. Attend from your computer March 19 from 1pm-2pm ET. Register here. (Source: Armada, March 2014)
New FDA Educational Resources Now Available
In recognition of Rare Disease Day 2014, the FDA haslaunched a new website resource which houses recorded educational topics about FDA and rare disease issues.Additional cross-cutting rare disease topics will continue to be added to this webpage over time. Some topics included are:  Essentials of Interacting with the FDA; Introduction to Patient Focused Drug Development; Regulatory Applications for Products Intended to Treat Rare Diseases. See more here. (Source: FDA.gov, March 2014)
Google Cloud Gets HIPAA Friendly
Google recently announced its cloud platform will be HIPAA-friendly and will support business associate agreements going forward. New HIPAA rules making Business Associates (BAs) accountable for violating HIPAA privacy and security rules had led to difficulties getting BAs to actually sign agreements. More information available here. (Source: Erin McCann, Healthcare IT News, 2/11/14).
 
Finding Value Of Health IT - It's More Than Just ROI
There's been a whole lot of capital invested in health information technology these past few years-is this money well spent? The benefits  of IT systems are not always easy to access. More than ROI, the value of health IT is demonstrated and measured in many ways. More here. (Source: Mike Millard, Healthcare IT News, 3/7/14).
GlaxoSmithKline's FDA Batting Average Tops The Industry
GlaxoSmithKline had the industry's best 6-year run of FDA nods for new drugs, leading its competitors by a wide margin, according to EvaluatePharma. Read more here. (Source: Damian Garde, FierceBiotech, 3/7/14).
 
Is Market Access Dead? Should It Be?
In this article, guest blogger, John Glasspool, explores the idea that Market Access is dead indeed and that we will be seeing a fundamental shift of perspective away from a company-centered (Market Access) and towards a patient-centered (Patient Access) view of the problem. Read more here. (Source: PharmExec, John Glasspool, 9/20/13).
 
Workshop - Adopting A Patient Reported Outcomes And Experience Based Approach To Diabetes Healthcare
This workshop is designed to help you identify where and how you would most benefit from implementing a patient reported outcomes (PRO) and experience (PRE) based approach in diabetes healthcare. More information available here. (Source: DHP Research, the patientoutcomesblog, 3/7/14).
 
How will ACA Cuts To Medicare Advantage Plans Impact The Program?
How will looming cuts that the Affordable Care Act makes to Medicare Advantage plans impact the program? medpage Today puts that question to Karen Davis, PhD of Johns Hopkins Bloomberg School of Public Health, Michael Morrisey, PhD of the University of Alabama at Birmingham, and Dan Ehike, PhD of the State University of New York. Their opinions ranged from little impact on patients to a great deal. Read more here. (Source: medpage Today, 3/7/14).
Are Insurers And Consumers Agreeing On What Factors Matter Most In A Health Plan?
Customer Service, premiums, brand/reputation - What's important to you in considering a health plan? PwC's Health Research Institute recently released survey results this week which highlights a disconnect between health plan leaders and consumers when it comes to important health plan factors. More information here. (Source: Alicia Caramenico, FierceHealthPayer, 3/6/13).
Capturing Emotions & Perpetuating Memories Through Painting
Check out our Featured HE Artist of the Week - Salome de Cambra, P&R and Market Access freelance consultant, painter and mucisian.  You can learn more about Salome and see some of  her oil painting here. If you, or someone you know, are interested in being a HE Artist, please contact HealthEconomics.Com
Attention Recruiters - This Just In...Special Opportunity To Meet Potential Candidates And Conduct Interviews Onsite In Tampa!
The Academy of Managed Care Pharmacy is excited to announce a custom package of Annual Meeting opportunities for managed care pharmacy recruiters! The "Career Connection" package makes it easy to promote your available positions and meet face-to-face with hundreds of skilled managed care professionals. Visit this link for full details or reach out to AMCP staff expert Kristine Bender. (Source: AMCP).
WEBINAR: Improve Business Process Effectiveness in a Payer Environment
Register to watch now!
This one-hour webcast introduces Business Process Management (BPM) and Operational Decision Management (ODM). Learn how BPM and ODM can help you connect staff, members and providers through systems and processes that enable the sharing of information contained in medical records, claims, risk levels and other vital data. 
ISPOR 6th Asia Pacific Conference
ISPOR 6th Asia Pacific Conference is happening in Beijing, China - September 6-9 2014! Online Abstract Submission is now open! Abstract Submission Deadline: March 20, 2014. More information available here. (Source: ISPOR, 2014).
 
New Gilead Hep C Drug "Cheaper Than a New Liver"
Sales for Gilead's new hepatitis C drug, Sovaldi, are stronger than originally expected. Sovaldi carries a price tage of $84,000 per 12-week treatment course. Anaylists expect it will surpass Lipitor as the biggest-selling drug by years end. PBMs are looking for ways to control drug spending, but payers may find the price of treatment less expensive than the price of a new liver. More here. (Source: FiercePharma, 3/7/2014)
ISPOR 6th Asia Pacific Conference
ISPOR 6th Asia Pacific Conference is happening in Beijing, China - September 6-9 2014! Online Abstract Submission is now open! Abstract Submission Deadline: March 20, 2014. More information available here. (Source: ISPOR, 2014).
 
Chronic Disease Progression - Forecasting Events, Costs, and QOL in Your Models
In this guest post in the tHEORetically Speaking Blog, Jacob Barhak, PhD, describes his Reference Model for Disease Progression and the recent advancements that improve the visual clarity and the accuracy for predicting chronic disease progression complications, morbidities, costs, and quality of life. Some fascinating work being done with this model. Read blog posting here; to be a guest blogger, contact Dr Patti Peeples at HealthEconomics.Com.
Risk Prediction & Personalized Medicine - We Got A Long Way To Go Baby!
Oncology, Stroke, Diabetes, Cardiology- These fields, and many more, are looking at the ways in which risk prediction and personalized medicine could potentially change the way patients are diagnosed and treated, but many of these approaches have a long way to go before their efforts will truly be effective. More information here.  (Source: Susan Hall, FierceHealthIT, 3/4/14).
 
Pfizer's Inlyta Reconsidered By NICE And Recommended
After recommending against making Inlyta available in March of 2013, NICE has now reconsidered and issued draft guidance after an appeal by Pfizer, as well as medical and patient groups. More information available here. (Source: PMLiVE, 3/5/14).
 
New VBID Research Offers 'Compelling' Data But Reinforces Long-Term Prospects
While proponents of value-based insurance design (VBID) say it can result in lower costs and higher quality of care, how to successfully design such programs and when to expect results continue to be debated and explored….Log in to read more here. (Source: AISHealth)
 
How Much Is Patients' Time Worth?
The Centre For Health Economics first newsletter of 2014, issue 19! Included in this issue are details of 4 recently completed research projects from CHE, Analysis of productivity in the NHS, the influence of cost-effectiveness results on NICE decisions and much more. CHE Newsletter available here. (Source: The University of York, Centre for Health Economics, March 2014).
 
Four Ways To Assure Americans Get High Quality Care Despite Narrow Networks.
Insurance companies with network restrictions steer customers toward certain providers and away from others. Ideally, they would steer their customers towards more efficient providers who provide high quality care, with little waste, lower cost and better outcomes. Unfortunately, this is not always the case. How can we assure Americans receive quality care despite narrow networks? Read here. (Source: Ezekiel Emanuel, The New York Times, 3/5/14)
 
Managed Care Digest Series - SANOFI
The nationally renowned Sanofi Managed Care Digest Series provides key benchmarking data that can help health care professionals assess value, control costs and develop business strategies. More information available here. (Source: AMPC).
 
ISPOR Board Of Directors - Election 2014 - Cast Your Vote!
ISPOR members have the opportunity to choose the leadership of this organization from a number of candidates with diverse professional training and work experiences. Use your voice! Vote Now! (Source: ISPOR, 2014).
Getting Real With Real World Evidence
In this CONNECTED COMMUNITY Podcast, Dr. Peeples interviews Jeff Trotter of J Trotter Research and Consulting.  Learn about Survey 2014: Real-world Evidence, and explore issues and trends relating to rationale, levels of evidence, regulation, data quality, analysis, communication, and key controversies in the development and use of real-world evidence. Podcast available here. (HealthEconomics.Com, 2014).
Webinar - Patient Reported Outcomes - Now Available On Demand!
This webinar reviews the results of a recently published study conducted by the PROMIS Initiative that tested the impact of Method of Administration on certain PRO measurement characteristics.  Within this context, the presenters will review the benefits and key questions that clinical trial sponsors should consider when implementing a Bring Your Own Device approach for ePRO data collection in pre-approval studies. Download available here (Source: ERT)
ERT Named Preferred Provider Of Key Quality Of Life Assessments
ERT has recently been announced a preferred provider for the administration of the EuroQol Group's EQ-5D patient reported outcome (PRO) assessment. More information available here. (Source: ERT, 2/18/14).
Medicaid Health Plans Need to Cozy Up to PBMs
Rising costs and increasing use of specialty pharmaceuticals are a big concern among Health Plans. Javier Menendez, RPh, associate vice president of pharmacy operations at Virginia Premier Health Plan, Inc., recently spoke at the Leadership Summit on Medicaid Managed Care, and said recent drug approvals would only increase the costs. He suggested that health plans pay close attention to their relationship with PBMs. More here. (Source: First Report Managed Care, 2/27/2014)
Avella study finds that pharmacist intervention saves almost $30,000 monthly
Medication non-adherence impacts clinical outcomes and contributes to rising costs. Avella, in partnership with the University of Arizona and the NIH, conducted a research study that reveals the impact of specific medication adherence strategies. The study sample included renal transplant recipients who were at least one year post-transplant and served by Avella. View their findings here. (Source: Avella, 2/27/2014)
Did you pass? BPS Announces Results of 2013 Exams
The Board of Pharmacy Specialties® (BPS) has announced results of the 2013 BPS specialty certification and recertification exams. A total of 3,247 pharmacists passed the exams in the six specialties currently offered by BPS: ambulatory care pharmacy, nuclear pharmacy, nutrition support pharmacy, oncology pharmacy, psychiatric pharmacy and pharmacotherapy. There are now 19,109 BPS board certified pharmacists, which represents an increase of almost 21% from 2012. Read more here. (Source: News-Line, March 2014)
ISPOR's News Across Central & Eastern Europe
This issue highlights current health policy trends, news, and outcomes research developments in Central and Eastern Europe. Furthermore, it emphasizes the many ISPOR CEE Network activities and educational initiatives led by the ISPOR Regional Chapters in the CEE region, including their presentations, activities, and attendance at the recent ISPOR 16th Annual European Congress in Dublin. Read more here. (Source: ISPOR, Dec 2013).
 
How A Performance Threshold Increase Affected General Practitioner Behavior in Scotland
Under the NHS, general practitioners (GPs) are paid based on a mix of factors, including a pay-for-performance element, the Quality and Outcomes Framework (QOF). In this article, OHE's Yan Feng and her colleagues investigate whether and how an April 2006 increase in the performance thresholds required for maximum payment under the QOF changed the behavior of GPs in Scotland. More information here. (Source: Yan Feng, OHE, 3/4/14).
 
First Drug Assessed By NICE's Highly Specialised Technologies Programme
The National Insititute for Health and Care Excellence (NICE) was recently unable to recommend Alexion's 'ultra-orphan' drug, Soliris, due to high cost. Soliris is used to treat atypical hemolytic uraemic syndrome (aHUS), an extremely rare blood condition. More information here. (Source: Thomas Meek, PMLiVE, 3/4/14).
NEW! Medical Device and Diagnostics Road Map Information for South Korea
ISPOR Global Health Care Systems Road Map has recently introduced - Medical Devices & Diagnostics Road Map Information for South Korea. Available here. (Source: ISPOR, Jan/2014).
NEW!! ISPOR Task Force Review Groups Available
Check out ISPOR's two new Task Force Review Groups!
Simulation Modeling Applications in Health Care Delivery Research - Emerging Good Practices Task Force, and
Patient and Observer-Reported Outcomes (PROS & OBSROS) Measurement in Rare Disease Clinical Trials-Emerging Good Practices
More information available here, including how you can take part in an ISPOR Task Force. (Source: ISPOR, 2013)
Significant Adherence Improvement & Cost Savings With Avella's Adherence Toolbox
Medication non-adherence is a serious widespread issue that impacts clinical outcomes and contributes to rising healthcare costs. As a result of this non-adherence, patients may experience preventable complications, disease progression, acute events and hospitalizations. You can view the findings of this research study, conducted by Avella, in partnership with the University of Arizona and the National Institute of Health, in this video. (Source: Avella Specialty Pharmacy).
 
Patient Assistance Programs - Added Cost Or Strategic Advantage?
Tony Olaes, Principal Consultant for the Blue Fin Group, brings up many questions and possibilities surrounding Patient Assistance Programs (PAP) and asks readers for feedback. Read more. (Source: Tony Olaes, Finsights, 2/27/14).
Express Scripts Drug Trend Report
Designed to serve the needs of employers, health maintenance organizations, health insurers, union-sponsored benefit plans, third-party administrators and government health programs, this publication features the latest research developments, timely trend updates, actionable data and relevant information on topical issues. More information here. (Source: Express Scripts)
 
Rating The Quality Of Observational Studies Of Comparative Effectiveness
Quintiles and the National Pharmaceutical Council have developed and tested the GRACE checklist to evaluate the quality and usefulness of observational research studies. This checklist was published in the March 2014 issue of Journal of Managed Care & Specialty Pharmacy and is available to download here. (Source: National Pharmaceutical Council)
Marketing- How Does Your Company Stand Out From The Rest?
This featured blog post on tHEORetically Speaking talks about the importance of finding what is important & unique about your company and communicating that with potential clients/customers in a way that makes you really stand out against everyone else. How do you do this? Read more here. (Source: tHEORetically Speaking, 2/27/13).
 
Healthcare Trends & Forcasts - Don't Miss Out On This Vital Resource!
This vital resource, now in its ninth year, includes results from the tenth annual Healthcare Trends and Forecasts survey conducted in October 2013. Forecasts covering payment and reimbursement, bundled payments, accountable care organizations, care management, the changing dynamic of health plans' product portfolios, best bets in shared savings and co-management, health plans’ impact primary care, the growth and challenges of shared savings models and the role of data analytics. Get your copy here. (Source: Health Resources Publishing).
Healthcare Trends & Forcasts - Don't Miss Out On This Vital Resource!
This vital resource, now in its ninth year, includes results from the tenth annual Healthcare Trends and Forecasts survey conducted in October 2013. Forecasts covering payment and reimbursement, bundled payments, accountable care organizations, care management, the changing dynamic of health plans' product portfolios, best bets in shared savings and co-management, health plans’ impact primary care, the growth and challenges of shared savings models and the role of data analytics. Get your copy here. (Source: Health Resources Publishing).
Analysis Aims To Better Understand The FDA
A recent study lead by Nicholas Downin, a fourth year medical student and at Yale School of Medicine, and leading authority on the FDA, examined the pivotal efficacy trials leading to 188 FDA drug approvals for 208 indications between 2005 and 2012. More information here. (Source: Tim Casey, First Report Managed Care, 2/19/14).
NICE Technology Appraisal Methods - What Changes Can You Expect?
The two main proposed changes to the methods guide for technology appraisals will allow the incorporation of burden of illness and wider societal benefits into what has become known as value-based assessment, with insights into how to accomplish this. Read more here. (Source: Ruth Howells, PMLiVE, 2/25/14).
 
NICE Technology Appraisal Methods - What Changes Can You Expect?
The two main proposed changes to the methods guide for technology appraisals will allow the incorporation of burden of illness and wider societal benefits into what has become known as value-based assessment, with insights into how to accomplish this. Read more here. (Source: Ruth Howells, PMLiVE, 2/25/14).
 
NICE Approves Bayer's Eylea For New Use
The National Institute for Health and Care Excellence published final guidance recommending Eylea for patients with visual impairment due to macular oedema. Eylea should provide stiff competition to Lucentis, it's rival from Novartis, considering Bayer's drug does not require monthly visits to a hospital for monitoring. More information here. (Source: PMLiVE, 2/26/14).
 
EMD Serono Specialty Digest, 9th Edition
A quantitative survey was fielded to health plan pharmacy and medical directors who are responsible for specialty drug-related services in their health plans. The survey was conducted between December 6, 2012 and January 9, 2013. You can find the survey results here. (Source: EMD Serono, Inc., 2013).
 
CVS/Caremark Insights Drug Trend Report 2013
CVS/ Caremark takes a look at the past, discusses the present and makes some forcasts for the future in this report. Improving the member experience, HCV Infection, Multiple Sclerosis, Shift to generics, Medicare and Medicaid: The year ahead, Market Trends and Forcasts, Drug trends & forecasts - you'll find all of this and more, here. (Source: 2013 focus: The Member)
Three Things You Need To Know About Big Data
What is all the hype over Big Data about anyway? Can it really put an end to medical errors, sub-optimal care, and poor outcomes? What can it NOT do? Read this blog post and learn more about When Analyzing Big Data Goes Wrong. (Source: Nick Emptage, tHEORetically Speaking, 3/26/13).
Three Things You Need To Know About Personalized Medicine
Are you familiar with the term, personalized medicine? Do you know the difference between personalized and precision medicine? In this tHEORetically Speaking blog post, Caitlin Rothermel explains: Three Things You Need To Know About Personalized Medicine. (Source: tHEORetically Speaking, 4/11/13).
Health Outcomes Teams: Small Numbers = Big Impact
A recent Cutting Edge Information Report found that compared to other pharma field forces, HOL teams do not maintain, or need, nearly as many outside reps to successfully deliver tremendous impact. Read more here. (Source: heraldonline.com, 2/20/14).
 
Can EUREQUO Improve The Quality Of Cataract And Refractive Surgery Again?
Two questionnaires will be included in the expansion with translation into 11 different languages. Read more here. (Source: Ocular Surgery News, 2/20/14).
Science Fiction, Medical Writing And A Small Hobbit - What Do These Things Have In Common?
Meet The He Artist Of The Week, Amanda Justice. Amanda has taken a story she wrote for a high school class and turned it into fiction series known as the Woern Chronicles.  A blend of science fiction and fantasy, backed by her background as a medical writer, Amanda's novels are sure to get your mind racing and are available on Amazon! Check out our HE Artist Of The Week, Amanda Justice, here.
Are You Familiar With Alberta's Updated Price Policy?
The update, effective February 20, 2014, touches the Alberta Price Confirmation, the pan-Canadian generic initiative price confirmation, the fixed pricing rule, the least cost alternative policy and the maximum allowable cost policy…Read more. (Source: Canadian Market Access, 2/19/14).
 
UK Has A New Diabetes Drug On The Market
Janssen Receives Draft NICE Recommendation And Launches Invokana The Same Day! The draft NICE guidance for Invokana in type 2 Diabetes is up for consultation until March 17. Use will be limited until a final positive guidance from NICE is received. Read more. (Source: PMLiVE, 2/24/14).
 
Contract Pharmacies - 4 Steps To Prepare For The 340B Program
The steps do not claim to solve for the concerns, but instead, give manufacturers the ability to manage eligibility and gain some insight into the new program. Read more here. (Source: Brian Barbash, Finsights, 2/21/14).
 
Will Biogen Idec's Oral MS Drug Get Final Approval From NICE?
NICE has rejected the use of Biogen Idec's oral multiple sclerosis treatment Tecfidera in draft guidance saying that Tecfidera was not a cost-effective use of NHS resources. Biogen Idec has until March 12 to submit further information with a final recommendation aimed for the summer of 2014. Read more here. (Source: Thomas Meek, PMLiVE, 2/21/14).
The New CMS Diagnosis Code - Will There Be A Smooth Transition?
The Centers for Medicare & Medicaid Services recently announced its plans to offer "end to end" ICD-10 testing for a small group of providers this summer. With such a significant transition, will this be enough? Should testing be opened to any interested provider? Read more here. (Source: Dan Bowman, FierceHealthIT, 2/20/14).
Healthcare In High Definition: A Trend Report
Catamaran is excited to introduce its 2012 Informed Trends Portal, a dynamic way to view and understand key trends from Catamaran and related insights within the PBM industry. More here. (Source: catamaran).
Clinical Trials - How To Keep The Patient From Breaking Up With You
A successful clinical trial must maintain high levels of patient recruitment, adherence and retention, but this proves to be a significant challenge for researchers. Enter Behavioral Economics (BE), based on the idea that our behavior is mainly unconscious, irrational and socially driven.  So how do we use BE in clinical trials? Read more here. (Source: tHEORetically Speaking, 9/06/13).
Germany - The "Wild Card" In Drug Pricing; How Will This Play Throughout Europe?
The law, which could come into force as soon as April,  is aimed at stopping wholesalers and pharmacies from basing their margins on list prices rather than the discounted prices, but the pharma industry fears this could trigger price falls elsewhere. More information here. (Source: Ulf Staginnus, HEALTH ECONOMICS BLOG, 2/18/14).
 
HealthEconomics.Com and J. Trotter Research & Consulting Launch Survey on Pharma Real-World Evidence
HealthEconomics.Com and J Trotter Research & Consulting are once again collaborating on an updated version of their survey which has tracked trends in real-world evidence over the past five years.  2014: Real-World Evidence - Challenges and Opportunities will launch on March 9, 2014, with results available in May. Organizations interested in sponsorship and/or participation see here for more information. (Source: PRWeb, 2/19/14).
Biotechnology Monitor & Survey - Marketplace Policies, Practices, and Perspectives
In this report, you will find: Survey results: Trends in the Management of Biologic Therapy; Attaining the Promise of Biotechnology, including research, risks, molecular markers, and genetic testing; Pay for Performance in Oncology, Measuring the Value of Biopharmaceuticals and a Q&A with Tom Williams, Executive Director of the Integrated Healthcare Association. More information available here. (Source:  AMPC)
So You've Written An Article - What's The Trick To Getting Published?
In this CONNECTED COMMUNITY podcast, Dr. Peeples interviews Caitlin Rothermel, principal of MedLitera, a small medical and health economics communications firm. Publication, Efficiency and New Guidelines are all covered. Listen to Getting Published. The Last Stage of Research, here. (Source: HealthEconomics.Com).
 
Take A Look At HealthEconomics.Com's New Connected Community Podcast Page.
The CONNECTED COMMUNITY™ Podcast Series explores relevant, controversial, or evolving issues in the field of health economics, market access, outcomes research, specialty pharmacy, HEOR medical writing, technology assessment, and more. Check out the CONNECTED COMMUNITY page here. If you would like to participate in a Podcast with Dr. Patti Peeples, contact us at info@healtheconomics.com.
Have You Heard About HealthEconomics.Com's Webinar Service?
HealthEconomics.Com webinars can take place both inside and outside HE-Xpo, the Pharma Industry's Only Online Virtual Community for Health Economics and Outcomes Research. HealthEconomics.com also offers an invitation package with the webinars! Interested? Read more here. (Source: PRWeb, 12/19/13).
 
ISPOR Educational Video Series - Check Out The New Topics
The Future Of Specialty Drugs
Will specialty drug spend surpass traditional drug spend? If so, how long will this take? Forecasts (by artemetrx) for traditional and specialty mediations were based on market trends in new drug approvals, new indications, generic availability, expected price inflation, and overall drug demand. Read more here. (Source: artemetrx).
Preventive Medicine - A Good Step For Reform?
What value does preventive medicine really have to patients? Will it actually save money? Will it stop chronic illness and disease? in this article, The Problem with Preventive Medicine, Nick Emptage discusses preventive medicine and comparative effectiveness. (Source: HealthEconomics.com, 4/18/13).
JMCP Embraces Specialty Pharma, with a Journal Name Change
This change will take place with the March issue and recognizes the growing importance of specialty pharmaceuticals to health care – not to mention managed care pharmacy. Read JMCP's February issue here. (Source: JMCP, February 2014).
 
Medicare D: The Trojan Horse We Always Knew It Was
CMS recently introduced the proposed rule on its intended reform of the Part D plan. What are the implications of this rule, and will it stand? What actions should be taken by Manufacturers, Pharmacies, Insurers and PBMs? Read more here. (Source: Bill Roth, Finsights, 2/14/14).
New Evidence Update From NICE
NICE Evidence Updates help to reduce the need for individuals, managers and commissioners to search for new evidence, and keep health and social care professionals up-to-date with new research. While Evidence Updates do not replace current accredited guidance and do not provide formal recommendations, they do highlight new evidence that health and social care professionals may wish to consider alongside current guidance. (Source: NICE, 2014).
Run Run As Fast As You Can - You Can't Catch This HE Man!
Meet Ken O'day, HealthEconomics.Com's Featured HE Artist. Ken develops health economics models at Xcenda and is also an accomplished triathlete! Just how good is his doggie paddle? Read here to find out! If you or someone you know would be interested in being featured in our HE Artist section, please contact HealthEconomics.Com.
LASER Announces Strategic Collaboration with H-Labs
LA-SER Analytica has announced a strategic collaboration with H-LABS Ltd in the area of scientific engagement and market access consulting. H-LABS was founded by Ed Godber to focus on the way in which engagement could increase the value of information submitted to decision-makers. Roman Casciano, the general manager of the Consulting & Analytics division of LASER Analytica commented: ‘’This strategic alliance is a tremendous opportunity for us to deepen our expertise and complement our market access consulting offer as our customers are increasingly pursuing scientific engagement to guide optimal development’’. Read more. (Source: LASER, 2/13/2014)
Orphan Drugs - Why Digital Should Be The Heart Of Your Marketing Strategy
There are many challenges to marketing orphan drugs. The need for awareness campaigns, the small number of patients who benefit from orphan drugs, and convincing payers of value together mean that one on one engagement is simply not a viable option. This is where the digital realm can be your friend. More information here. (Source: PMLiVE, 2/10/14).
 
Will German Epilepsy Patients Have Access To Fycompa Once Again?
After deciding to withdraw Fycompa from the market last year, rather than sell it at Germany's HTA agency approved price, Eisai's epilepsy drug, Fycompa could be re-entered onto the market as Germany takes another look at pricing. Read more here. (Source: PMLiVE, 2/11/14).
Mammograms - Improving Survival But Not Mortality - Do You Know The Difference?
Do you know the difference between survival rates and mortality rates? It's a very important difference, explained very well in this video, by Dr. Aaron Carroll of the University of Indiana. (Source: James Hamblin, The Atlantic, 2/12/14).
 
AMCP - Call For Monitors And Volunteers
Volunteering is a great way to give back to your association! The Academy of Managed Care Pharmacy is now accepting applications for Education Session Moderators, Booth Volunteers and Conference Buddies. More information here. (Source: AMCP, 2014).
 
What Defines Quality Health Care, And How Is That Related To Costs?
Join this discussion TODAY to discuss this critical issue with special guests in a live, G+ online event. TODAY at 2pm ET. Sign up here. (Source: Google+)
 
Nominate Yourself! Volunteer for a NASP Committee
The National Association of Specialty Pharmacy (NASP) is seeking professionals working in the specialty pharmacy industry who are interested in volunteering on a NASP committee. Self-nominations are encouraged. The NASP was founded in 2012 and represents specialty pharmacy professionals in all practice settings and highlights the unique value its members bring to patients and the healthcare system. More here. (NASP, 2/11/2014)
How Do You Put A Value On End Of Life Treatment?
OHE Explores Social Preferences And Burden Of Illness In Value-Based Assessments
 
Dr Donna Rowen from the University of Sheffield, presents her recent research on defining social preference. The research is intended to inform changes in 2014 in NICE's method of value assessment. 
OHE's Koonal Shah recently presented his findings at the University of Oxford as part of the Health Economics Research Seminar Series at the University of Oxford. Koonal's presentation and Dr Rowen's presentation slides are available here. (Source: OHE, 2/11/14).
Company Says No To Downsizing & Rehiring - Seeks Out Training From Xcenda
In this case study, learn how Xcenda helped transform a sales team, unprepared to launch a new oncology product, by building new skill sets while keeping them in the field. Download case study here. (Source: Xcenda).
 
Nominations For The Robert F. Allen Symbol Of H.O.P.E. Award Are Underway
The Robert F. Allen Symbol of H.O.P.E. (Helping Other People Through Empowerment) Award honors individuals who have made outstanding contributions to promoting cultural diversity within health promotion or who have demonstrated significant achievement in serving the health promotion needs of underserved populations. Deadline for nominations is April 25, 2014. More information available here. (Source: American Journal of Health Promotion).
 
PROMs - Linked Data Required For Accurate Recruitment Rates
The routine use of patient reported outcome measures (PROMs) aims to compare providers as regards the clinical need of their patients and their outcome. Simple methods of estimating recruitment rates based on aggregated data may be inaccurate. Case study results here. (Source: 7th Space Interactive).
 
Call For Research Proposals: Affordable Priorities Towards Universal Health Coverage
The Middle East and North Africa Health Policy Forum (MENA HPF) is a non profit regional organization dedicated to the development of sustainable policies that improve health particularly for those who are most disadvantaged. The MENAHPF is pleased to invite submission of research proposals under the topic, Affordable Priorities Towards Universal Health Coverage. Submission deadline is April 10, 2014. More information available here. (Source: MENA HPF).
AMCP Members - Have You Cast Your Vote?
AMCP is holding elections for President Elect and three Board of Directors seats. All AMCP Active Members are encouraged to vote in this year's election. Ballots must be received no later than February 21, 2014.  More information here. (Source: AMCP, 2014).
 
A New Way to Think About “Product Value”…Take a Lesson from Stanford MBA Students
A Group of Stanford MBA Students was given $5-10 and challenged to make as much money as they could with it in just one week. What was the point of this assignment? What would you do? Read more here. (Source: Quora)
 
Not to be missed! 10th Annual Specialty Pharmacy Summit & Expo
The latest version of the agenda for the 10th Annual Specialty Pharmacy Summit & Expo occurring on May 5-9, 2014 at the Wynn Hotel is now online! Hosted by Armada Health Care, this program is packed with the most current information on the specialty pharmacy industry and includes seminars and sessions by the country's foremost thought leaders and Pharma trade executives. View the agenda here. (Source: Armada, 2/10/14)
How Can Specialty Competencies Help Achieve ACO Goals?
Attend Part 2 of this free webinar series brought to you by Armada Health Care, Avalere Health and SPAARx.This webinar will discuss ways that specialty pharmacy providers can contribute to the achievement of accountable care goals. February 19, 2014 at 1pm. Register today. (Source: Avalere Health, 2/10/2014)
HEOR - 3 Steps To Using Social Media Effectively
Is social media important in your HEOR? What might the benefits be? Think past your limitations and read tHEORetically Speaking's The ABCs of HEOR Social Media. If you would like to be a guest blogger for tHEORetically Speaking, please contact HealthEconomics.Com. (Source: theoretically Speaking).
What Did You Think Of The ISPOR 2012 Budget Impact Analysis? Read This Review
Should off-label use be included in a BIA? What did you think of the recommended reporting format? Do BIAs hold any relevance for Decision Making? Read more here. (Source:  Elsevier, Value In Health, 2014).
 
Improving The Usefulness Of Budget Impact Analyses
The report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force updates the previous guidance published in 2007. With these caveats in mind, this review believes that following the guidance provided by the task force will meaningfully improve the validity, transparency, and flexibility of BIAs provided to payers and other users in an increasing variety of different settings. More here. (Source: Elsevier, Value In Health, 2014).
 
ISPOR Task Force Report - Budget Impact Analysis - Principles Of Good Practice
Budget impact analyses (BIAs) are an essential part of a comprehensive economic assessment of a health care intervention and are increasingly required by reimbursement authorities as part of a listing or reimbursement submission. Objectives: The objective of this report was to present updated guidance on methods for those undertaking such analyses or for those reviewing the results of such analyses. Read more. (Source: Elsevier, Value In Health, 2014).
 
How Much Are Health Outcomes Affected By Hospital Resources?
This report contains information collected by the NHS in England. Since 2009, they have collected PRO data for four elective procedures. Their research produces a number of important insights about the best approaches for using PRO data, the determinants of health outcomes for individual patients, and whether and what variations in outcomes can (and cannot) be explained by differences across hospitals in resource use. Read more here. (Source: OHE, 2-06-14).
Will Specialty & Community Hospitals Survive Reform?
In an unexpected consequence of reform, insurers are dropping specialty and community hospitals from provider networks! The federal government, however, may not tolerate excessive network cuts and are proposing new policies. More information available here. (Source: Jane Antonio, FierceHealthPayer, 2/07/14).
 
5 Reasons Why You Should Attend This Workshop
The primary focus of this workshop on cognitive interviewing, is on how to effectively develop verbal probes and conduct verbal probing for evaluating measurement equivalence across data collection modes. Read here for 5 reasons why You should attend Cognitive Interviewing For Evaluating Measurement Equivalence Of Electronically Migrated PRO Instruments. (Source:  DHP Research, thepatientoutcomesblog, 2/04/14).
What If Shopping For Healthcare Were More Like Shopping For A Car?
It's hard to believe in this day in age, when we are able to get on the internet and research price, safety, and pretty much anything we want to know about any purchase we make, that the same is not true with healthcare. How are we to make decisions with such little transparency? Read more Pricing Cars Like Healthcare, by Debra Gordon. (Source: Debra Gordon, tHEORetically Speaking).
Can Payers Close The Gap Between Medical & Pharmacy Benefits?
Data from Zitter Health Insights’ Managed Care Biologics and Injectables Index shows that a consistent, overwhelming majority of payers believes that the potential benefits of integrating medical and pharmacy management outweigh the costs and challenges, but find their organizations' management of this process to be sub-par. Read more. (Source: Cassandra Habura, zitter Health Insights, 1/28/14).
 
Saama's New Business Consulting Practice - Helping You Harness Big Data
Saama recently announced their new Business Consulting Practice for Analytics and Big Data Initiatives, which aims to democratize the access to data and the analytical processes that can enable action. Read more here. (Source: saama, 2014).
Big Data's Impact On Innovation Workshop - Only A Few Days Left To Register!
Leveraging Big Data II: What Does It Mean For Improving Product Development And Health Care. This conference, sponsored by the University of Maryland Center of Excellence in Regulatory Science and Innovation and the FDA, in collaboration with the National Pharmaceutical Council, will take place on February 11, 2014. It will bring together researchers from the FDA and other government agencies, industry, and academia to continue the M-CERSI dialogue and scientific exchange on big data and its role(s) in and impact on medical product development. (Source: University of Maryland School of Pharmacy, 2014).
Multiple Sclerosis Remains A Hot Topic Among Manufacturers And Payers
Multiple sclerosis remains one of the most frequently discussed therapeutic areas between pharmaceutical manufacturers and payers, driven in large part by visits from oral MS agent manufacturers. Read more here. (Source: Tracy McCarrick, zitter Health Insights, 1/17/14).
 
University Of Sheffield Seeks Dissertation Hosts
The students will be ideally suited to undertake a cost-effectiveness analysis, or related quantitative research. They will have developed models using TreeAge, Excel and Simul8. They will also have taken modules in Medical Statistics, Operational Research Techniques and Health Economics. Students undertake the placement from July to September inclusive (full time). If you are potentially interested in hosting a student, or would like to find out more information, please email Jon Tosh. Deadline for proposed placements is March 14th.(Source: University of Sheffield)
 
What Do You Think About CVS' Stand Against Tobacco?
Effective October 1, 2014, CVS Caremark will discontinue the sale of cigarettes and tobacco products at more than 7600 locations. They will also be launching a program to help members quit smoking! Read more here. (Source: First Report Managed Care, 2/05/14).
Is The Diabetes Health Profile Going Paperless?
Potential advantages of moving from paper to an eDHP: Accelerated treatment and intervention evaluation, Enhanced treatment adherence, New avenues for predictive outcomes and tailored therapeutics, Improved understanding of patient populations and compare subgroups. More information available here. (Source: DHP Research thepatientoutcomesblog, 2/04/14).
 
Specialty Pharmacies: Going Smart Instead Of Going Big
In this Connected Community podcast conversation, Richard Carlson from Blue Fin Group, and Dr Patti Peeples, CEO and Founder of HealthEconomics.Com discuss how Pharmaceutical Manufacturers and Specialty Pharmacies are 'going smart' instead of 'going big' when thinking about data, analytics and contractual requirements. More information here. (Source: Richard Carlson, Finsights, 02/04/14).
 
Submission Request: Health Economist Influence On Policy In US vs Other Developed Countries
Applied Health Economics and Health Policy is planning a themed issue on the question of whether health economist in the US have a different influence on policy than health economists in other developed countries. Submission DEADLINE is June 30, 2014. For suggested topics and other information on submissions, check here. (Source: Adis, 2014)
 
ACOs - Time For A Come Back?
Experts Plan To See More Plan-Sponsored ACOs On The Insurance Exchanges, some are even projecting that up to two-thirds of the country could be covered by ACOs in the next five years. All agree the success of ACOs will depend on their ability to bend the cost curve and not just improve quality. Read more here. (Source: Neal Learner, AISHealth, 1/27/14).
 
There's A New Journal In Town - The American Journal Of Health Economics
The inaugural issue of the American Journal of Health Economics, the official journal of the American Society Of Health Economists, will appear in the first quarter of 2015 and submissions are being accepted NOW! For more information on journal content, submissions, check here. (Source: MIT Press Journals) 
 
Have Payers Given Up On The Digital Consumer?
While payers have drastically pulled back on App launch experimentation, they seem to be focusing efforts in more precise areas such as: payer-owned consumer data aggregation platforms, biometric tracking initiatives, the next generation of social media platforms and more. Full Article available here. (Source: Brian Dolan, mobihealthnews, 1/27/14).
 
80 Economic Evaluations Have Been Added To NHSEED
University of York - Centre For Reviews And Dissemination. More information here. (Source: University of York, 2014).
 
100 Systematic Reviews Have Been Added To DARE
University Of York - Centre For Reviews And Dissemination. More information here. Source: University of York, 2014).
 
Call For Papers - Hematology/Oncology
American Health & Drug Benefits readers are invited to submit manuscripts for the May 2014 issue themed issue, Hematology/Oncology; including original research, cost-effective analyses, evidence-based comprehensive reviews, case studies, and industry surveys/trends. Submission Deadline is March 17, 2014. More information available here. (Source: American Health & Drug Benefits, Nov/Dec 2013).
Journal of Managed Care Pharmacy - Expanding Its Reach to Specialty Pharma and More!
The Academy of Managed Care Pharmacy recently announced the first major expansion of the Journal of Managed Care Pharmacy. The expansion targets specialty pharma, ACOs, medical directors, and more. More information available here. (Source: The Sacramento Bee, 02/03/14).
 
Big Government = Big Data: How Much Information Is The FDA Really Collecting?
FDA's "Mini-Sentinel" project recently released a report on the massive amounts of personally identifiable health data it has been collecting. As of 2012, the database contained data on more than half the United States. How secure is this data? Read more here. (Source: Pharma Marketing Blog, 02/01/14).
 
PMPRB Published Final 2013 Price-Adjustment Factors
The actual rate of consumer price index (CPI) inflation for 2013 was 0.9%. The final year-over-year price increase cap for 2013 is 1.4% (= 1.5 x 0.9%). More details available here. (Source: PMPRB, January 2014).
NASP Specialty Pharmacy EXPO Opens for Registration
The National Association of Specialty Pharmacy (NASP) has opened registration to attendees and sponsors for its Specialty Pharmacy EXPO, scheduled for March 31 - April 4 at the University of South Florida's Center for Advanced Medical Learning and Simulation (CAMLS), a state-of-the-art facility in downtown Tampa. The EXPO brings together leaders and decision makers from the industry to discuss the latest issues and trends. It offers valuable networking opportunities with colleagues and exhibitors as well as 90 hours of accredited, specialty pharmacy education. Registration for the event is available here. (Source: NASP, 1/30/2014)
From Dolls To Adults - This HE Artist Has You Covered!
Meet Luminita Vopsaroiu, HE Artist of the Week! During her 18 years as a medical statistician, Luminita continued her life long passion as a textile artist. What was once only a hobby soon became an additional source of income as her client base began to grow! Read more about Luminita here. If you or someone you know would like to be featured in the HE Artist section, please contact HealthEconomics.com. We'd love to share your story!
ISPOR Global Health Care Systems Road Map
An overview of country-specific health care delivery systems focusing on reimbursement and pricing approval processes for pharmaceuticals, medical devices and diagnostics, which includes validated decision models that define decision makers and the decision-making processes for coverage, reimbursement, and pricing. More information here. (Source: ISPOR).
ISPOR - Pharmacoeconomic Guidelines From Around The World
Pharmacoeconomic (PE) guidelines can be used as a standard for preparation of studies to be included in application for reimbursement, a guide for designing and conducting a study, or a template for evaluating the economic study reports. More information available here. (Source: ISPOR)
The Negative Side Of An Inappropriately Positive Title
This article contains correspondence to the editor of The New England Journal of Medicine regarding an article by Von Hoff et al., Oct 31 issue, entitled "Increased Survival in Pancreatic Cancer With nab-Paclitaxel Plus Gemcitabine." The title was described as inappropriately rosy, citing modest benefits and substantial toxic effects. Read more here. (The New England Journal of Medicine, 1/30/14).
 
Who Will Provide Funding For PCORI's Continued Growth?
PCORI May Look To The NIH, The FDA Or To Health Industry Partners.‘I sure hope the NIH finds ways to use the network,’ said [PCORI Executive Director Joe Selby], who also noted that [NIH Director Francis Collins] is providing input into the development of the network...Collins has been a cheerleader of the new efforts. ‘NIH is thrilled that these organizations have come together and agreed to create a single, overarching network that will be seamlessly integrated using electronic databases,’ he wrote… Paid Subscription Required. (Source: Rebecca Adams, CQ HealthBeat, 1/29/14).
Has Congress Stopped The Push To Repeal PCORI?
During the run-up to the passing of the Affordable Care Act, the Patient-Centered Outcomes Research Institute was the target of much Republican criticism. But based on her interactions with congressional members, Project HOPE’s Gail Wilensky says there’s no desire now on Capitol Hill to end the institute’s activities. Purchase Required to read more. (Source: Gregory Twachtman, The Pink Sheet Daily, 1/29/14).
Walgreens Brings Big Data Analytics To Healthcare Clinics
The convergence of Inovalon’s data-driven patient assessment tool, Electronic Patient Assessment Solution Suite (ePASS®), and Healthcare Clinic at select Walgreens creates a unique offering within the health plan and retail clinic industry. By integrating data analytics, they expect to help improve patient care and outcomes. More here. (Source: Business Wire, 1/30/14).
 
AMCP Warns: Proposed Part D Changes Could Undermine Program
AMCP urges against changes to preferred networks, mail-order pharmacy and MTM in Part D- saying these changes would increase costs to the program and beneficiaries as well as roll back any recent progress. Read more here. (Source: Digital Journal, 1/30/14).
For Clever Ways to Present Health Outcomes Data, Look to the….State of South Carolina!
Who would have thought that a state government group would deduce one of the most clever ways to present healthcare data, for easy interpretation by consumers (and healthcare professionals).  Check this out by the state of SC on diabetes, ESRD, and Obesity. Read more. (Source: Anthony Brino, GovernmentHealthIT, 1/30/14).
Is Bigger Always Better? Big Data vs. Smart Data
This article does a good job and breaking down the differences between big data and smart data and discusses the benefits of using smart data in marketing pharmaceuticals. Read more here. (Source: Joe G, CBI, 1/24/14).
 
Upcoming Webinar On Clinical Trial Design And Development Strategy
Webinar: Transforming Clinical Development Strategy And Performance With Real-World Data
Context Matters CEO, Yin Ho, will be on a panel for the upcoming free webinar, Transforming Clinical Development Strategy and Performance With Real-World Data. The webinar is sponsored by Oracle Health Sciences and Pharmaceutical Executive. More information here. (Source: Context Matters, 2014).
 
More Regulation or Better Regulation?
Professor Alan Maynard, University of York, delivered the 20th OHE Annual Lecture, Contracting For Quality In The NHS. His thoughts on fixing patient care deficiencies in the NHS differ than those recommendations in the Francis Report. He suggest that better regulation is needed, not necessarily more regulation. Read more here. (Source: OHE, 1/28/14).
 
DIA & PCORI Collaborate To Bring You This Complimentary Webinar
Webinar: February 5, 11am-12:30pm
Patient-Centeredness and Engagement in Clinical Research: Opportunities for Industry, explores how PCORI and other stakeholders are advancing patient-centeredness and engagement in research, what we know so far about the impact of this trend, what we hope to learn in the future, and the implications for industry. (DIA, 2014).
 
Are Hospitals Profiting From Patient Complications?
This blog, Hospital Profits Higher When Surgical Patients Develop Complications was written by Debra Gordon in response to a study published in the Journal of the American Medical Association, April 17, 2013. (Source: Debra Gordon, tHEORetically Speaking, 2013).
 
tHEORetically Speaking Invites You To Share Your Thoughts
The Official Blog Of HealthEconomics.com, tHEORetically Speaking, invites anyone in the field of healthcare value and market access to share their insights, predictions, and general thoughts on the state of global health economics.  If you’d like to share with our audience, please contact us!  Good jokes are always welcome too.
Top Five Metrics Evaluated To Measure ACO Success
HINs ACO Survey & Chart Of The Week:
HIN's ACO survey captured how 138 healthcare organizations are participating in ACOs, including who administers the ACO, which providers participate in the ACO, the top components of an ACO, and much more. Find out what the top five metrics evaluated to measure ACO success are here. (Source: HIN, 1/29/14).
 
Snakebite: At Some Point, Healthcare Costs Need to Be Defendable
Snakebite Victim Charged $89,000 For 18 Hour Hospital Stay! The hospital charged $81,000 for anti-venom medication which can be found online for $750? Don't worry- I'm sure the hospitals has a good explanation for this….Read more here. (Source: Dylan Stableford, YAHOOnews, 1/28/14).
 
Satisfaction Goes Social
What happens when patient [dis]satisfaction goes social? Are payers, providers and third party stakeholders missing an opportunity? Read "Satisfaction Goes Social" by Laurie Gelb and join the conversation. (Source: tHEORetically Speaking, 3/15/13).
 
Are Public Healthcare Information Exchanges In Jeopardy?
With doctors not trusting the records or seeing a meaningful connectivity, grant money running out and provider networks and hospitals considering private HIEs, it seems inevitable. Public HIEs need more effective processes, revenue streams and business models if they want to stay in business. Read more here. (Source: Susan Hall, FierceHealthIT, 1/28/14).
 
Is Hepatitis C Cure Worth $1000/day?
Gilead's new 12 week treatment cost $84,000! Such stratospheric prices for this new drug and many other breakthrough treatments has caused insurers to look at alternatives to covering high-priced hepatitis, diabetes and other treatments. What does this mean for patients? More information here. (Source: Drew Armstrong, Bloomberg Personal Finance, 1/27/14).
 
PatientsLikeMe CEO - Keynote Speaker For DIA 2014 50th Annual Meeting
Jamie Heywood is one of the foremost practitioners using technology to transform the future of health care. He is the founder of PatientsLikeMe, a personalized research and peer care platform that allows patients to share in-depth information on treatments, symptoms and outcomes. He is also the founder of ALS TDI, the world’s first nonprofit biotechnology company. He will be presenting during the opening plenary on Monday June 16 for DIA 2014 50th Annual Meeting. (Source: DIA, 2014).
 
Is Bigger Always Better?
Data, data, data. Blogger Richard Carlson discusses how Manufacturers are often "buried in specialty data complexity and how the incompleteness and inaccuracies overwhelm and make the data difficult to use. The problem is that many manufacturers have gone “Big” with their specialty pharmacy data and have not gone “Smart” or “Right Size"." Are you asking the right questions about your data? Read more. (Source: Finsights, 5/20/13)
Need a Comprehensive Review of the Specialty Pharmacy Model?
Then this seminar is for you. This two-part seminar offers an in-depth analysis of the specialty pharmacy industry, including: historical and future market analysis, the channel structure and the provider service model. It concludes with an interactive Q&A session with an expert pharmacy panel on the opportunities in this marketplace. This seminar is offered at the 10th Annual Specialty Pharmacy Summit & Expo. Learn more. (Source: Armada, Jan. 2014)
BAYER - Making Waves With Pricing And Charges of Racism
India has been following its own patent laws in an attempt to give its people access to a new cancer-fighting drug, Nexavar. Bayer is the manufacturer of Nexavar which cost $69,000 annually compared to the Indian pharmaceutical company Natco Pharma Ltd who was able to offer it for just $177!! The response from Bayer's CEo will shock you! Read about it here. (Source: Adam Peck, ThinkProgress, 1/26/13)
 
Value-Based Assessment In The UK - How Will It Be Implemented?
In this presentation, Adrian Towse explains, VBA replaces ‘value-based pricing’, which as originally proposed in the UK was intended to achieve several objectives including broadening the definition of value. Adrian’s presentation reviews important issues in defining value, demonstrates how past policies aimed at value have affected the availability of some medicines, and suggests ways forward under the modified, VBA approach. More here. (Source: OHE, 1/23/14).
 
Is PCORI Falling Short Of Its Potential?
Critics claim the health law did nothing to control costs, but has the potential to bend the cost curve over the long term. Can the institute carry out a bold enough research agenda to live up to that potential? Paid Subscription Required. (Source: Bronwyn Mixter, Bloomberg BNA, January 2014).
 
Does ISPOR See The Real Importance Of Innovative Technologies?
This discussion regarding newer technologies, and more specifically Symbolic Math tools, continued between Anderew Briggs and the author, Jacob Barhak, via email. Now made public, interested parties are welcome to view a summarized transcript here. (Source: Jacob Barhak, Sim, 1/13/14).
 
Ben Goldacre Makes The Case For Greater Transparency In Clinical Trials
In this podcast, Pharma IQ discusses the issue of clinical trial transparency with Dr. Goldacre, with a focus on how it will affect industry and why pharma companies have taken differing strategies in response to the campaign. Listen to podcast here. (Source: Pharma iQ, 1/21/14).
Pharmaceutical Companies - How Will Brazil's Drug Price Index Affect You?
The Brazilian government did not publish the drug pricing formula used in September as it normally does.  Where does this leave pharmaceutical companies trying to prepare for 2014? Read more here. (Source: Katie Bell, FirstWord Pharma, 1/20/14).
 
3rd Annual Conference On Healthcare Markets - Call For Papers
Northwestern University's Kellogg School of Management will be hosting the 3rd Annual Conference on Healthcare Markets on May 16, 2014.  For a list of possible topic areas and more information of manuscript submission click here. (Source: Northwestern University, January, 2014).
Who's Ready To Samba? Check Out This Week's HE Artist!
Meet LeeAnn Braun, Associate Director, Market Access and Outcomes Strategy at RTI-HS and Competitive International Latin Dancer!! Just how does one enter the world of competitive dancing? Find out more about this HE Artist here. If you or someone you know would like to be a featured HE Artist, please contact Healtheconomics.com.
 
Special Issue Of Risk - Call For Papers
The intent of this special issue of Risks, Risk And The Economics Of Health, is to offer a forum for the examination of the impact of risk on the behavior of consumers, providers and insurers, and ultimately the implications for the efficiency of the health care system. We are calling for high quality papers discussing these issues, both from theoretical and empirical perspectives. DEADLINE for paper submission is May 15, 2014. More information available here. (Source: risks, 2014).
 
UK - How Much Does Your Location Affect Your Access To Medicine?
This report was developed by a joint working group involving the Department of Health (DH), NICE, HSCIC and the pharmaceutical industry to assess how well patients are able to access the medicines approved for use by NICE. Read more. (Source: FirstWord Pharma, 1/22/14).
What Are The Top Journals For Today's Health Economist?
The intention of this paper is to create a list that exposes possible research outlets for health economists and to help demystify the relative rankings of such outlets using established objective measures. Download here. (Source: Social Science Research Network, 5/4/13).
 
Dublin Congress Extends Deadlines!
Due to high demand on their system, Dublin Congress has decided to extend deadlines for organized session/individual abstract submissions and the early bird rate for congress registration. 
 
New Deadlines are: 
Organized session and individual abstract submission deadline has been extended to Tuesday January 28, 2014 at 10:00pm EST.
 
Congress early bird registration has been extended to Wednesday January 29, 2014 at 10:00pm EST
 
Any questions or concerns please contact:
Paula Richardson, Membership Director, iHEA
 
Price Gouging & Racketeering - Top 10 Offending Hospitals
National Nurses United's (NNU) research arm, the Institute for Health and Socio-Economic Policy, conducted research on hospital pricing practices. It found evidence of what the group calls "price gouging" and "racketeering." Here are the top 10 hospitals with inflated prices. (Source: Managed Healthcare Executive, 1/06/14).
 
9 Factors That Drive Healthcare Cost
From the Miller Center, University of Virginia, 9 Factors That Drive Healthcare Cost.  More here. (Source: Managed Healthcare Executive, 1/09/14).
 
Pharma Pricing Breaking News
Pharmaceutical pricing strategies go well beyond what the market will bear, but what really works? Breaking news stories for the pharmaceutical industry in the pricing, market access, and health outcomes arena in HealthEconomics.Com, January 13th, Newsletter. Read Here. (Source: PRWeb, 1/17/14).
 
Reflections On Operationalising Value Based Assessment
A Slideshow From The Office Of Health Economics. Value-based pricing, as originally proposed in the UK, was intended to achieve several objectives, including broadening the definition of value. This presentation reviews important issues in defining value, demonstrates how past policy aimed at value has affected the availability of some medicines, and suggests ways forward under the revised, value-based assessment approach. See more here. (Source: OHE, 1/13/14).
 
Need A Guide to Value-Based Reimbursement?
The Guide to Value-Based Reimbursement: Profiting from Payment Bundling, PHO Shared Savings, and Pay for Performance explores emerging models of episode-based payments, physician-hospital organizations and physician bonus structures. Purchase your copy here. (Source: HIN, 2013).
Pharma Firms- Pick Your Penalty!
Faced with a very limited staff, the National Pharmaceutical Pricing Authority (NPPA) is finding itself unable to calculate the companies' penalty and has instead left that up to the individual companies. So... how do you think this will turn out? Read more here. (Source: Business Standard, 1/20/14).
 
Achieving Quality in ACOs: Are They Ready to Maximize the Value of Pharmaceuticals in Patient Care?
NPC Webinar NOW AVAILABLE ONLINE! Did you miss this week’s webinar from the National Pharmaceutical Council, on accountable care organizations (ACOs), that explored how ready ACOs are to implement the structures and processes needed to maximize the value of pharmaceuticals? Speakers outlined the activities that ACOs are doing well, and shared insights on where there is room for improvement. Available here. (Source: NPC, January 2014).
 
Webinar On The Health Insurance Exchanges Tomorrow!! January 23!
This Webinar from Zitter Health Insights will cover topics such as: Anticipated enrollment in the exchanges at the disease state level, Factors that consumers consider when enrolling in an exchange plan, Demographic profiles of uninsured consumers, Maximum monthly premium & out of pocket cost these consumers are willing to pay and more. Please contact Michala to RSVP, and join meeting here. (Source: Zitter Health, 1/22/14).
What's So Special About Specialists' Care?
This article takes a look at specialists' care as compared to physicians. They're making more money that's for sure, but why? Do the procedures take longer? Do they require more intensive training? What percent of American health care expenses come from Specialist care? The answers may surprise you! Read more. (Source: The New York Times).
 
How Do You Put A Value On Health At The End Of Life?
A Slideshow from the Office of Health Economics, Valuing Health at the End of Life. More here. (Source: OHE, 1/21/14).
 
Take A Look at The State Of American Health Care From A Behavioral Economics Perspective
Featured speaker Dr. Douglas Hough has written a new book which looks at the state of American health care through the lens of behavioral economics. With it, he hopes to encourage patients, physicians and policy makers to make better choices for the nation's health and well-being. Podcast available here. (Source: World Congress, 2014).
 
How Much Privacy Do You Give Up With Patients Like Me?
Some patients signed up with Patients Like Me are unhappy about the companies privacy policy and feel the companies reach goes too far.  This article covers some ways in which the company could be more clear about their policies to make sure that all parties are happy with the partnership. Read more. (Source: World of DTC Marketing.com, 1/19/14).
 
What Is The Real Cost Of Medication Noncompliance?
Dr. Hayden Bosworth addresses the cost of medication noncompliance and why different groups in the healthcare sector need to come together in order for solutions to work. Podcast available here. (Source: World Congress, 2014).
 
Pharma & Tobacco Companies - Can We Trust Either?
How much honesty can we expect from industry-backed research? According to this author- not very much. Which is why he has called for medical journals to ban the publication of research funded by pharma companies. Read more here. (Source: PMLiVE, 1/17/14).
 
Interview With Beate Wieseler, IQWIG
Germany has emerged as one of Europe's most financially stable counties. One reason for this is the government's effort to keep costs low. The following article interviews Dr. Beate Wieseler on many aspects of Germany's spending in the area of healthcare. Read more here. (Source: PMLiVE, 1/8/14).
 
Call For Papers: Deadline Extension
This themed issue of Applied Health Economics and Health Policy is set to explore  the question of whether health economist in the US have a different influence on policy than health economists in other developed countries.  For a list of specific questions that could be addressed by articles in this issue, or information on submissions, click here. (Source: Adis, 2014).
Now Available - Published Thought Piece On The Value Of Surrogate Endpoints In The EU3
CBPartners has evaluated several recent launches across specialty and oncology therapeutic areas to understand how G-BA / IQWiG, NICE, and the HAS view the use of surrogate endpoints in making a value-based argument, in order to better understand and mitigate the barriers likely to be encountered by manufacturers throughout the pricing and reimbursement process. Please contact Rachel Beckerman at CBPartners for a copy. (Source: Linkedin, Jan, 2014).
 
Looking To Amp Up Your New Product Development?
Moving from “Cost-Based, Product Driven” to “Value-Based, Customer Driven.” Using the value-based, customer driven process ensures that from the moment the new product is released, customers will already be aware of how it will add value in their business processes. Read more here. (Source: PROS, 1/14/14).
 
Despite Price Caps, Indian Pharmaceutical Sales Recover
After dipping this past fall after the implementation of the New Pharma Pricing Policy (NPPP), the overall volume growth has started to rebound. IPCA Laboratories, Glenmark Pharma and Sun Pharma lead December 2013 domestic growth. Read more. (Source: Business Standard, 1/19/14).
 
Wondering How To Prepare For A Virtual Career Fair?
On January 23, 2014, between 9am-1pm, HealthEconomics.Com is hosting the first ever virtual Career Fair focused on HEOR, PRMA, and Data Analytics in HE-Xpo. What can employers and job seekers do to prepare for this? This blog contains important information you need to know, including an interview with Klein Hersh Executive Recruiters. Read more here. (Source: tHEORetically Speaking, 1/16/14).
India maintains price controls on time-release drugs
The National Pharma Pricing Authority (NPPA) had originally included this set of drugs while fixing price caps last year, but the ministry recently told the authority that time-release set of drugs should be excluded. What happened next? Read here to find out. (Source: The Economic Times, 1/15/14).
 
Can German Physicians Save The Drug-Assessment Program?
The new administration says it will scrap the system, but many argue that this step will make it more difficult for doctors and patients to access independent information and fear the return of a time when drug makers were able to set their prices freely in Germany. Read more here. (Source: PharmaTimes, 1/15/14).
 
ABPI Code Updates Are In Effect - What Does This Mean For Pharma?
The latest update to the Association of the British Pharmaceutical Industry's (ABPI) Code of Practice came into effect at the beginning of the year.  For information on grace period, read full article here. Details of the change along with a PowerPoint presentation and a copy of the 2014 Code are available on the ABPI's website. (Source: PMLiVE, 1/16/14).
NASP Practice Parameters Project – Call For Volunteers Due Monday, January 27
NASP Members, Your Participation In This Project Is Key To Its Success! NASP is recruiting volunteers with knowledge and experience in the specific therapeutic categories to serve on Advisory Groups that will help spearhead this project. Volunteers are still needed in the following, initial therapeutic categories: Diabets, Hep C, HIV, Oncology-Breast, Oncology-Multiple Myeloma, Oncology-NHL. More information available here. (Source: NASP, 2014).
 
How Can You Use Analytics To Streamline Care And Maximize Revenue?
In this eBook, readers will learn how to use data analytics tools to gain actionable insights from clinical, financial and administrative data, which can help hospitals target services and personalize care. Download your copy of Data Analytics: Actionable Information To Improve Healthcare,  today! (Source: FierceHealthIT, 2014).
Confounding and Missing Data in Cost-Effectiveness Analysis: Comparing different methods

According to Harkenen et al, common approaches in  do not adjust for confounders. In nonrandomized studies this can result in biased results. Parametric models such as regression models adjust for confounders, but don't handle skewed costs and large proportion of $0.  This article suggests ways to handle these issues.  More here.  (Source: Health Economics Review 2013)

Grant Opportunity: Infrastructure Development Program in PCORI
Deadline December 20, 2014

More information.
WP243 Thought Leader Compensation: US vs. EU
Global strategies for establishing fair-market value payments for opinion leaders can prove challenging. This white paper provides a guidepost to determine European fee schedules and compensation limits. It also outlines the differences observed between US and EU hourly rates.  (Source:  Cutting Edge Information)

Read more.  (Note:  form must be completed to download)